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Abstract 
A biofilm can be defined by a community of microbes coexisting within a self-produced 
protective polymeric matrix. Exopolysaccharide (EPS) is a key component in biofilms and a 
contributor to their virulence and pathogenicity. The cellulose bacterial synthesis complex is one 
such EPS system that is found in many Enterobacteriaceae, including Escherichia coli and 
Salmonella spp., and is responsible for the production and secretion of the EPS cellulose. BcsC is 
the periplasmic protein responsible for the export of the exopolysaccharide cellulose and was the 
focus of this research. Sequence homology comparisons and structural predictions between 
BcsC, and the previously characterized alginate export proteins AlgK and AlgE indicate similar 
roles in facilitating the translocation of EPS across the bacterial cell wall. However, there are 
discrepancies between the systems, such as the purpose of several additional tetratricopeptide 
regions (TPRs) contained within BcsC compared to AlgK. To better understand the role that 
BcsC plays in cellulose export structural characterization of this protein was pursued. Six protein 
constructs that together cover overlapping portions of BcsCs TPR region were successfully 
expressed and purified, four of which were further analyzed with SAXS and screened for crystal 
formation. SAXS data was merged with a pre-existing protein data bank file of BcsCTPR 1-6 to 
identify similar regions and provided conceptual renderings as to the orientation and size of the 
protein. Promising crystal hits from BcsCTPR 12-21 and BcsCTPR 1-15 were obtained, optimized and 
sent for X-ray diffraction, with resolution results between 12 and 2.8 Å.  A complete dataset for 
BcsCTPR 1-15 has since been collected and structure solution is ongoing through a combination of 
molecular replacement and selenomethionine (SeMet) labelling techniques. Preliminary  SeMet 
crystals are promising, but currently appear thinner than native crystals and additional 
optimization may be required before suitable X-ray diffraction data can be obtained.  
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1.0 Introduction 
1.1 Escherichia coli and Salmonella spp. 
Escherichia coli and Salmonella spp. are among the leading causes of foodborne diseases. 
Foodborne diseases are estimated to cause illness in as many as 600 million people, of which 
approximately 420,000 people die annually, with almost one third of them being children under 
five years of age (1). The United States alone has an estimated 48 million cases annually of 
foodborne illness, with a predicted economic impact of 77.7 billion dollars in health-related costs 
(2). In the United States, Salmonella accounts for approximately 3.6 billion dollars per year of 
these health-related costs (3). Without intervention the statistics may only increase, which makes 
research towards the goal of alleviating the economic burden and physical pressures related to 
this crisis of paramount importance.    
 While Salmonella spp. are typically viewed as pathogenic (4), many strains of E. coli are 
harmless and are part of the natural microbiota of the mammalian intestinal tract (5). However, 
some strains of E. coli can be deadly to human hosts (ie., strain o157:H7; ) and have been 
responsible for numerous outbreaks of contaminated food and water illnesses (6). A local 
outbreak was exemplified by the small rural town of Walkerton, Ontario, where a pathogenic 
strain of E. coli led to an epidemic causing the death of 7 individuals and 2,300 others became ill 
through water consumption (7). This strain of E. coli (o157:57) was alone responsible for 390 
outbreaks in the United States between 2003 and 2012 (8). More recent outbreaks of E. coli 
infections have been linked to ground beef (9) and two separate flour product recalls, one in the 
U.S (9) and in Canada (10). Evidence of outbreaks from  multidrug-resistant strains of 
Salmonella (11) call further attention to the need for understanding the mechanisms by which 
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bacteria survive in a host during an infection, but also the mechanism by which these organisms 
persist in our food/water distribution systems is necessary. 
1.2 Biofilms 
Bacteria exist in a unicellular state where the planktonic cells are free swimming and can 
form a multicellular complex, where the cells are sessile and exist in a biofilm (12). Bacterial 
biofilms can be described as heterogeneous structures that may contain different populations of 
microorganisms, which are encompassed by a matrix (composed primarily of 
exopolysaccharides) that facilitates attachment to a variety of surfaces and interfaces (including 
both inert and/or organic) to facilitate growth as a micro-ecosystem where by-products from 
different organisms are cross-utilized (13, 14). Biofilm formation is the primary survival strategy 
utilized by the majority of infectious bacteria (15–17). Biofilms are prominent within the human 
body persisting as chronic infections, entrenched on medical devices, and in the oral cavity (15). 
In these environments, biofilms contribute resistance to disinfectants (like chlorine) of up to 
1000 times (14). According to Lewis (2001), an estimated 60% of infections in humans are due 
to the formation of biofilms; thus increasing the necessity for research and strategies in 
prevention and treatment (19). Biofilms also permit bacteria to flourish in a wide variety of 
environments, where pH, temperature, humidity, nutrient content and other factors vary widely 
(20–22). These protective features of a biofilm are particularly important from a health 
perspective, as the biofilm matrix also increases bacterial resistance to immune 
detection/clearance, antibiotics and disinfectants (15, 17, 21, 23).  
1.3 Biofilm Formation and the role of c-di-GMP 
The second messenger c-di-GMP is a widely conserved soluble intracellular signaling 
molecule of paramount importance in controlling biofilm formation (21). The regulatory 
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functions of c-di-GMP production are controlled by several effectors at multiple levels 
(transcriptional, translational, and at the protein level). For example, two groups of enzymes with 
antagonistic activities exert control over the c-di-GMP turnover rate in the bacterial cytoplasm 
(25, 26). A c-di-GMP molecule is enzymatically synthesized from two guanosine triphosphate 
(GTP) molecules through the action of diguanylate cyclases (DGC), which contain a GGDEF 
amino acid consensus sequence domain; whereas, the hydrolysis of c-di-GMP into linear pGpG 
or two guanosine monophosphate (GMP) molecules is controlled by phosphodiesterases (PDE) 
that contain EAL or HD-GYP domains (27–31). The cytoplasmic flux in concentrations of c-di-
GMP oscillates with environmental changes exerted by the activites of these opposing enzymes 
(DGC and PDE proteins) and is directly related to the production of exopolysaccharides (EPSs), 
virulence, adhesion, motility, and cell morphogenesis in a diverse range of bacterial species 
including E. coli and Salmonella spp. (24, 26, 30, 32, 33). C-di-GMP, through binding to 
riboswitches and acting as an effector to a variety of proteins, is responsible for regulating 
multiple two component systems (34–36). For example, high concentrations of intracellular c-di-
GMP will typically lead to EPS synthesis, loss of motility (flagella), increased adhesion and 
aggregation; thereby favouring biofilm formation (24, 26, 32); whereas, a low concentration 
results in the opposite effect, motility and highly invasive phenotypes. Therefore, given that c-di-
GMP is highly conserved across a diverse range of bacterial species, this signaling molecule 
represents a common mechanism of regulation and control over biofilm formation and dispersal 
(32, 37). 
Once c-di-GMP levels rise, biofilm formation by independent cells is triggered to begin, 
and colony growth progresses through four main stages of development (38, 39). The main 
stages of biofilm formation are attachment, aggregation, maturation, and dispersal (Figure 1). 
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Attachment of a cell to a substratum, also known as adhesion, is mediated by the characteristics 
of the surface and the cell (13, 40). The properties of the surface that might affect attachment are 
hydrophobicity, charge, and texture (22), whereas, the characteristics of the cell surface that 
would impact attachment are the presence of pili, fimbriae, flagella and/or extracellular 
polymeric substances (41, 42). These bacterial macromolecules are important factors in 
promoting attachment by aiding the bacteria in overcoming repulsive forces or binding specific 
structures on a surface until permanent attachment features are in place/expressed (18). Notably, 
the initial step is called reversible attachment (Figure 1; panel A), while the second step of 
biofilm formation, known as aggregation, is where irreversible attachment takes place.  
   
Figure 1. Stages of Biofilm Formation. Biofilm development is initiated by (A) reversible 
attachment of individual cells to the substratum, which may require motility. The second step (B) 
in attachment is irreversible adherence with exopolysaccharide and pili and loss of motility 
appendages, followed by aggregation through cell proliferation. The third stage (C) is marked by 
the continued growth of the biofilm, presence of solvent channels and heterogenic biofilm 
structures that become established along with production of extracellular polymeric matrix and 
cell-cell interactions. The final stage (D) illustrates individual bacteria being released from the 
biofilm that may again begin the process somewhere else (modified from (43)). 
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The second stage of biofilm formation is signified by the alteration of the cell surface that 
assists with the development of a monolayer and initial aggregation of the bacteria (Figure 1; 
Panel B) (41). For example, intracellular increase of c-di-GMP levels influence the 
downregulation of motility appendages and the upregulation of EPS and fimbriae/pili; thereby 
leading to irreversible attachment to a surface (38, 44, 45). Bacteria then continue to aggregate 
and adhere to one another resulting in the creation of microcolonies (13). The maturation stage of 
the biofilm matrix leads to the continued growth of microcolonies into multilayered structures 
where solvent channels begin to form and are actively maintained to allow bacteria access to 
nutrients, water, and oxygen (Figure 1; Panel C) (15, 46). As the biofilm continues to mature, 
many different shapes can be adopted that are often influenced by environmental factors, such as 
pH, ionic strength, hydrodynamic shear, nutrient supply, species present in the biofilm, surface 
temperature, and/or host conditions (13, 20–22). For example, specific conditions lead to the 
formation of monolayers, multilayers (mushroom or pillar like 3D structures), and even pellicles 
at the air-liquid interface (23, 47).  
In mature biofilms, particularly within types that are involved in chronic infections, there 
exists a subtype of persister cells (48). These cells are not mutants, but instead are phenotypic 
variants of wildtype cells (48, 49). Persister cells are believed to be created by an accumulation 
of toxins in the bacterial cell that forces the cell into metabolic stasis (49, 50). While dormant, 
these cells may encounter antibiotics, yet often are not destroyed because the cell is not actively 
metabolizing or dividing. Persister cells can, thus, be multidrug tolerant without acquiring any 
additional defence mechanisms for subverting antibiotics (50). In addition, mature biofilms are 
known for fostering conditions ideal for horizontal gene transfer (conjugation, transfection 
and/or transformation) in which antimicrobial resistant genes can be passed rapidly throughout 
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members of the biofilm (23, 43). Thus, metabolizing cells can also actively acquire antimicrobial 
resistance in a biofilm setting. The rise of antimicrobial resistance in conjunction with biofilm 
formation has led to an increasing concern from a public health view.  
As the mature biofilm grows in size, some cells are separated from nutrient sources or 
exposed to detrimental environmental conditions and, thus, the bacteria have developed 
mechanisms to disperse from the biofilm (Figure 1; Panel D) (39, 47). In this final stage of 
biofilm development, termed dispersal, the bacteria leave the biofilm through 
desorption/detachment (passive separation) or through dispersion (active separation) (39). Active 
dispersal mechanisms are initiated by the bacteria themselves (eg., enzymatic or chemical), while 
passive separation (eg.,  erosion or sloughing) are due to external forces (51). As the bacteria 
make the transition from sessile to free swimming, they increase the expression of certain 
appendages for propulsion, and downregulate the production of EPS and other irreversible 
attachment structures (38, 47, 52). 
1.4 Bacterial EPS 
P. aeruginosa is one of the most widely studied organisms partly due to the role of the 
bacterial biofilm produced by this organism during infection of Cystic Fibrosis (CF) patients 
(53). In the CF lung, a human genetic mutation within the CF transmembrane conductance 
regulator (CFTR) gene results in improper clearance of mucus secretions from airway passages 
(53, 54). Accumulation of mucus provides an ideal environment for the attachment and 
colonization of opportunistic organisms, like P. aeruginosa (54). Within the CF lung, P. 
aeruginosa exacerbates the problem due to the production of a biofilm, which is predominantly 
composed of the EPS, alginate (composed of mannuronic and guluronic acid) (54). Production of 
alginate during infection of the CF lung is often linked to a poor prognosis for the patient (55). 
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As a result, there has been a wealth of research surrounding the production and effects of this 
polymer in conjunction with improving mitigation strategies for infection by P. aeruginosa. 
Bacterial cellulose is also an EPS that has numerous applications and economical 
significance. Cellulose, characterized by β(1-4)-glycosidic linkages, is the most abundant 
biopolymer on earth, and is found in vascular plants, algae, and bacteria (56–58). Plant cellulose 
has the additional polymers, lignins and hemicelluloses present, whereas, bacterial cellulose is 
formed as a pure polymer (59). Bacterial cellulose contains hydrogen bonds between the fibrillar 
units that provide strength and flexibility, allowing changes in shape to conform to different 
surfaces (60). Bacterial cellulose is naturally hydrophilic and is ordered into nano and 
microfibrils, which can allow for the formation of a hydrogel due to the binding of large amounts 
of water (59, 60). These examples only hint at the dozens of potential applications in drug design 
and delivery systems, cosmetics, as well as food and food packaging materials that have been 
proposed to be possible with this polymer (61). Furthermore, bacterial cellulose has promising 
biomedical applications due to its low immunogenic potential and biocompatibility (62). 
 In addition to its economic importance, bacterial cellulose has serious health impacts and 
has been identified in many bacteria including several species of Gluconacetobacter xylinus (63), 
Enterobacter (64, 65), Salmonella spp. (66), and E. coli. (5, 66). Although not all bacteria that 
produce cellulose biofilms are harmful, several species of Salmonella spp. have proven to be 
virulent within a host. For example, a study by Solano and colleagues (2001), found that biofilm-
forming strains of Salmonella enteritidis were highly virulent compared to non-biofilm forming 
strains when tested in a chicken infection model (67). A subsequent study by Solano and 
colleagues (2002), indicated that cellulose was not required for virulence in S. enteritidis (68). 
Using a chicken infection model, cellulose deficient strains were still virulent, yet the negative 
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cellulose mutant strains were highly susceptible to chlorine treatment where the wildtype was 
chlorine resistant (68). Taken together, these studies suggest that although cellulose production 
may not be required for virulence, it will increase survival. Moreover, Domenico and colleagues 
(2017) have suggested a multistage strategy for Salmonella typhi: colonization, followed by 
chronic persistence, and toxin production (4). S. typhi is known for its role in gallbladder cancer 
due to release of a carcinogenic toxin and has the capacity for survival as a biofilm within the 
gallbladder and on gallstones (4). Biofilms have been found in asymptomatic and symptomatic 
carriers in the harsh high-bile environment with antimicrobial properties, which is in a location 
that provides a direct route to release toxins to several susceptible target areas (4). Thus, as the 
biofilm provides the survivability to invade and colonize the host, the bacteria can then detach 
from biofilm and invade host cells while other the bacteria maintain the biofilm, leading to the 
process of chronic persistence (4). From the literature, many different applications for bacterial 
cellulose exist, in addition to the evidence that cellulose plays an important part in the chronic 
persistence of biofilms that can maintain virulence, thereby, making the understanding of its 
synthesis and export from the bacterial cell of consequential significance. 
1.5 EPS biosynthesis 
The focus of the present research is the cellulose biosynthesis pathway. However, many 
of the biosynthetic steps of microbial cellulose have been inferred from studies on the more 
characterized alginate biosynthetic pathway (69). The inference between the two pathways is due 
to the similarity between the proteins and enzymatic steps that occur in the synthesis and export 
of the polymers across the bacterial cell wall (Figure 2). Thus, a brief analysis of the alginate 
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biosynthetic pathway will first be presented, followed by the cellulose biosynthesis pathway.
 
Figure 2. Graphic Representation of the Alginate and Cellulose Biosynthetic Systems. Each 
pathway component is indicated on the schematic and colour-coded according to predicted 
similar functions as follows: green, exopolysaccharide modification enzymes; yellow, synthase; 
orange, transmembrane anchor; red, β-barrel porin; purple, TPR; The black line specifies the N-
terminal lipid anchor of AlgK. Please note that BcsC is one continuous protein but it was colour 
coded with the alginate system to show homologous regions. Through the two systems, the 
polysaccharide indicated is polymerized and transported via its respective synthase following c-
di-GMP binding. In the periplasm, polysaccharide modifying enzymes act on the 
polysaccharides prior to export by the TPR/ β-barrel protein regions (modified from (69)). 
 
The algD operon (alg824KEGXLIJFA) encodes the proteins required for the 
polymerization and export of alginate (69). Briefly, poly-β-D-mannuronic acid is synthesized 
from guanosine 5'-diphosphate-mannuronic acid at the inner membrane, while its polymerization 
and export is believed to be facilitated by the synthetase Alg8 and the c-di-GMP receptor Alg44 
(70, 71). Polymerization and transport across the inner membrane is thought to be regulated by 
the binding of c-di-GMP to the PilZ domain on Alg44 (70). Additional evidence from deletion 
mutants suggest that AlgX and AlgG may assist in directing the alginate polymer across the 
periplasm, as well as protecting it from the periplasmic alginate lyase, AlgL (72, 73). The outer-
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membrane lipoprotein AlgK (Figure 3), thought to be composed of 10 TPR domains, is proposed 
to act as a scaffold where other periplasmic Alg proteins can interact (74). AlgK is proposed to 
conduct the mature alginate polymer to the integral outer-membrane 18-stranded β-barrel 
protein, AlgE, which enables the passage of alginate through the outer membrane (75).  
Although a lack of definitive evidence of a direct interaction between AlgK and AlgE exists, 
support from mutant and localization studies suggest that AlgK contributes to the localization of 
AlgE (69). Additionally, evidence from homologous proteins, BcsC, PelB, and PgaA (involved 
in the export of cellulose, Pel polysaccharide, and poly β-1-6-GlcNAc, respectively), are all 
predicted through bioinformatics analyses to be large two-domain proteins with tandem-TPR and 
β-barrel regions, analogous to a fusion of the AlgK/AlgE protein complex (69). 
 
         
 
Figure 3. A Surface Model Illustration of AlgK in Three Orthogonal Alignments. Conserved 
residues on the surface of the protein have been identified by the researchers as possible binding 
sites for protein-protein interactions and are indicated with purple and green colour (modified 
from (74)). 
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Cellulose synthesis is encoded by the bacterial cellulose synthesis (bcs) operon bcsABZC, 
of which BcsA and BcsB are known as the catalytic core of the inner membrane (analogous to 
Alg8/44 from the alginate system – Figure 2) (76). BcsA contains a PilZ domain at its C-
terminus that binds c-di-GMP, and catalyzes cellulose polymerization from UDP-activated 
glucose in a process similar to that of the alginate system (31, 70, 77, 78). BcsB, a periplasmic 
protein anchored to the inner membrane by a transmembrane helix, provides stability to the 
transmembrane region of BcsA that is essential for catalysis (77). BcsB is theorized to initially 
direct the cellulose polymer from the cytoplasmic membrane into the periplasm through two 
carbohydrate-binding domains (77). BcsZ is a periplasmic glycosyl-hydrolase with endo-β-1,4-
glucanase activity that is believed to facilitate the degradation of EPS much like AlgL (72, 79), 
yet little is known regarding its interaction with BcsB-BcsA or BcsC (74, 76, 78). In the 
periplasm, BcsC has a TPR domain analogous to AlgK (Figure 3) that is likely responsible for 
mediating the passage of EPS through the periplasm to the 16 stranded β-barrel region 
(analogous to that of AlgE) that traverses the outer membrane (75, 78). Of particular note to this 
thesis is that homologous proteins from separate EPS biosynthetic systems (eg., cellulose, Pel 
polysaccharide, and poly β-1-6-GlcNAc) have conserved TPR regions of varying lengths that 
may correspond to specific requirements for each of these systems. Indeed, a review of the 
literature on TPRs (outlined below) also indicates that TPRs can serve multiple roles through the 
binding of protein, carbohydrates and even DNA, but these possibilities are still relatively 
unknown for the related proteins (BcsC, PelA and AlgK) from the EPS biosynthetic systems.   
1.6 Tetra-trico-peptide repeats (TPRs) 
Tetra-trico-peptide repeats (TPRs) are present in a wide variety of proteins involved in 
many different functions (80–83). This is due to the capacity to serve as a protein scaffold and 
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mediate protein-protein and protein-carbohydrate interactions (80–82, 84). A TPR is a versatile 
structural motif that consists of 34 amino acid tandem repeats (80, 85) comprising a degenerate 
consensus sequence of small and large hydrophobic amino acids (Figure 4; 82, 83). Interestingly, 
there are no completely invariant residues present, yet some residues are highly conserved in 
TPR domains (83, 86). The tertiary structure of the canonical TPR motifs is a helix-turn-helix 
fold (83). The adjacent parallel packing of TPR units adopt a succession of repeating anti-
parallel α-helices and produces an overall super-helical structure (83). The residue between 
adjacent TPR motifs affects the type of twist given to the super-helix (82, 83), which forms 
concave and convexly curved exteriors (Figure 5) that are flexible (87). These properties in 
combination with the variation in amino acids throughout the tandem arrays of TPR motifs are 
proposed to allow for a diverse binding of ligands, which often occurs at the concave surface but 
can infrequently occur along the convex surface, as well (83). 
Proteins that consist of TPRs can bind a diverse group of ligands in alternate binding 
locations (83). Ligand binding is believed to be specific and can occur within a populated 
cellular environment. To accomplish this, not only do individual residues along a particular 
surface contributing to binding (eg. charge and hydrophobicity differences can attract separate 
ligands), but multiple distinctive TPR folds are used as interaction platforms that can present 
multiple interfaces for specific binding with ligands (83). Binding of TPR proteins to their 
ligands has been suggested to be achieved by multiple complex factors, including hydrophobic 
pockets, charge, amino acid type, hydrogen bonding, electrostatics and coordination of surfaces 
(83). Although characteristics of TPR binding have been studied, it is still difficult to predict 
how specific TPR motifs will bind a specific ligand. This problem is largely due to the fact that 
there is a dearth of TPR structures containing bound ligands in the protein structure databases. 
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Part of the reason for this may be due to the fact that X-ray crystallography is a protein structure 
determination method that relies on ordered proteins, which may be problematic with the amount 
of conformational flexibility inherent in TPR binding to ligands (83). Although flexibility within 
a TPR protein is not often evident through examination of the crystal structure, one example was 
recently found that illustrated the extreme flexibility of a TPR that can exist in multiple 
conformations, due to hinge regions (87). Hinge regions have been found to exist between 
individual TPR motifs that provide the ability to change conformation (87). For example, in 
MamA, a hooked shaped magnetosome-associated TPR containing protein, the linker region 
provides enough flexibility for binding a second TPR domain, which induces a change in 
conformation of the peptide to a helical state. This novel function provides evidence that TPR 
proteins can exhibit considerable elasticity that may contribute to an abundance of different 
functions across diverse species. 
 
                   
Figure 4. TPR Motif Representation. TPR proteins characteristically contain a basic helix-
turn-helix fold of a duplicated, degenerate 34 amino acid sequence. The N-terminus is at the top 
and the C-terminus are at the bottom.  
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Figure 5. TPR Motif Surface Structure. Convex and concave surfaces of a TPR-containing 
protein (modified from (88)). 
1.7 BcsC 
The cellulose export protein BcsC, the protein of interest for this thesis research, has a 
predicted involvement in the transport of cellulose across the outer membrane (74). Genetic 
mutants involving BcsC in Acetobacter xylinus have indicated that BcsC is required for cellulose 
synthesis in vivo, but only BcsB is required for cellulose synthesis in vitro (89). One reason for 
this may be that cellulose is not being exported. In the Salmonella typhimurium MAE52 strain, 
cellulose was produced, yet mutating BcsC resulted in a severe reduction in biofilm formation 
and no expression of cellulose (66). BcsC is comprised of over 1,100 amino acids and is 
predicted to contain a C-terminal 18-stranded β-barrel region in the outer membrane proceeded 
by an extensive N-terminal TPR in the periplasm. The TPR region of BcsC is predicted to 
contain between 18 and 21 TPRs, which contrasts with AlgK (10 TPRs) and PelC (19 predicted 
TPRs) from other EPS biosynthetic systems. The reason for this discrepancy in TPR region 
length between the analogous proteins remains unknown, yet other key differences exist between 
their respective pathways. For example, the alginate pathway is believed to have several more 
proteins in the periplasm than the cellulose pathway. A number of these proteins (i.e., AlgX, 
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AlgG, and AlgL) have been proposed to assist in periplasmic passage of alginate in conjunction 
with AlgK, which may act as a scaffold for the assembly of these proteins (74). However, in the 
Bcs system there are far fewer accessory proteins to assist BcsB-BcsA and BcsC with the 
passage of cellulose through the periplasm (Figure 2) (77). This may partly account for the 
increase in the amount of TPRs in BcsC compared to AlgK, yet the specific mechanisms of the 
structure and function of BcsC remain largely uncharacterized to verify this theory.  
Recently, a study of BcsCs TPR region cloned from Enterobacter CJF-002, yielded the 
structure of BcsCTPR1-6 (Asp24-Arg272) solved to a resolution of 3.27Å and presented small 
angle X-ray scattering (SAXS) data of BcsCTPR1-17 Asp24-Leu664 (90). The crystal structure of 
BcsCTPR1-6 was helical with 14 α-helices, 12 of which formed TPRs α1–α2, α3–α4, α6–α7, α8–
α9, α10–α11, and α12–α13, while the other 2, α5 and α14, were not believed to belong to TPR 
motifs (90). The crystal contained five monomers in the asymmetric unit and three different 
conformations were observed. Following superimposition of the five monomers, each of the 
three conformations showed differences at the turn region (between α5–α6) and in the C-terminal 
half of each TPR (α6–α11), which extend in different directions (90). This apparent flexibility in 
structure was suggested to have a hinging effect on the C-terminal super-helix and the effect of 
this non-TPR region was proposed to assist in changing the direction of the super-helix (90).  
When discussing the SAXS data presented by Nojima and colleagues, it is important to 
note that Asp24-Leu664 was designated as BcsCTPR1-17, yet their bioinformatics predictions 
suggested that the full length TPR region of BcsC contained 19 TPR motifs (90). This differs 
from the preliminary Weadge lab analysis of BcsC which indicated 18 TPR motifs, it is unclear 
whether this was due to a difference in the genome of Enterobacter CJF-002 and E. coli K12 or 
differences in the analyses. When parsing the SAXS and crystallography data, Nojima and 
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colleages proposed that BcsC contains 6 super-helices in total that are connected by five 
hinge/non-TPR regions (90). The non-TPR regions were suggested to be involved in directional 
changes of the super-helices and might allow the BcsC TPR regions to form a unique structure 
aiding in the transport of emerging cellulose chains (90). Due to the discrepancies in TPR 
regions, and the resolution obtained from their model, many questions remain with respect to the 
structure of BcsCs TPR region in addition to the possible interactions this domain may have with 
neighboring periplasmic regions of BcsZ and BcsA-B.   
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2. Research Need 
 Bacterial cellulose synthesis and export processes is significant to many bacterial species 
and is integral to biofilm formation and propagation in these organisms. Although bacterial 
cellulose research has expanded into many different areas, such as food and food packaging, 
cosmetics, drug design, and drug delivery systems (61), the primary implications for bacterial 
cellulose research, with respect to this thesis, is found in the medical field due to its role in 
pathogenesis. For example, bacterial biofilms are utilized by many bacteria that have been 
implicated in chronic and persistent infections (15, 16). Furthermore, biofilms can provide a 
mechanism to survive in harsh environments in order to inflict pathogenicity on the host and lead 
to a variety of ailments, including cancer (4, 16, 91). Despite this, insufficient information 
regarding their exopolysaccharide biosynthetic structures and mechanisms exists. Worldwide 
foodborne diseases are estimated to infect 600 million people annually, resulting in 420,000 
fatalities (1). The United States alone averages 48 million cases each year, causing a predicted 
economic burden of 77.7 billion in health-related costs (2). Recently in North America, 
outbreaks of E. coli have been linked to beef, flour, and produce (10, 92, 93), with some strains 
that have proven resistant to many varieties of antibiotics (93). A similar situation exists with 
Salmonella outbreaks that have been reported in chicken, turkey, and even cereal (94–96). As it 
seems there is no end in sight, additional research is crucial to alleviating the constant pressure 
caused by these bacteria both medically and economically, as the majority of bacteria exist 
within biofilm communities (97, 98). In addition, the study of bacterial cellulose proteins is of 
paramount importance to our food and water security and can consequently provide improved 
knowledge of biofilm production as many bacterial pathogens, such as Salmonella and E. coli  
employ biofilms as a protection strategy (99–101). 
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 Recently, many molecular insights into the polymerization and transport of bacterial 
cellulose have been made (76–78, 90, 102). However, little is known of how the final steps in 
export of the polymer occur. BcsC is a key cellulose export protein in this process, believed to be 
essential for proper biofilm formation (66, 90) and, thus, presents a significant target for 
preventing and controlling biofilm production, bacterial expansion, and disease progression. 
BcsC is a member of a large class of exopolysaccharide export proteins (including AlgK), which 
are inherent components of biofilm biosynthetic apparati from species across the bacterial 
kingdom. Thus, a greater understanding of the role of BcsC is likely to have widespread 
implications in the control and disease prevention of many pathogenic bacteria, but also possibly 
in promoting the colonization of potentially beneficial bacteria (eg., probiotics). Current 
bioinformatical knowledge and research on BcsC in the Weadge lab has indicated that BcsC 
interacts with cellulose and predicts that BcsC may contain partially hydrophobic character that 
could theoretically be involved in ligand binding (previous work by Emily Wilson and Alex 
Anderson). From this preliminary data, we hypothesize that structural investigation of the N-
terminus of BcsC will confirm that it contains a series of TPR folds and that this region is 
important in ligand binding. These results will ultimately provide further insight into the role of 
BcsC in cellulose export. For example, a structural model will aid in the identification of 
possible substrate binding regions, hydrophobic interactions, and/or protein-protein interaction 
surfaces that can be further explored in additional functional and phenotypic experiments.  
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To address our hypothesis, we will perform the following objectives: 
Objective #1: Protein expression and purification of the series of protein constructs (Table 1 
results section) of the BcsC TPR domain.  
Objective #2: Perform extensive crystal screening of the TPR protein constructs for conditions 
that stabilize the purified protein constructs (dynamic light scattering) and are amenable to 
protein crystal formation. Promising conditions will then be optimized to refine the 
crystallization process so that the resulting crystals are suitable for X-ray diffraction data 
collection. 
Objective #3: Build structural models of the protein constructs of BcsC through a combination 
of X-ray crystallography and small-angle scattering experiments.  
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3. Materials and Methods 
3.1 Reagents, Chemicals, and Media 
The chemicals purchased from Fisher Scientific were EDTA-free protease inhibitor, 
sodium chloride, tris(hydroxymethyl)aminomethane (Tris). In addition, Coomassie stain and 
destain were prepared using chemicals also obtained from Fisher Scientific. The products 
purchased from BioBasic were BcsC synthetic gene constructs, Tryptone powder, isopropyl β-D-
1-thiogalactopyranoside (IPTG), and yeast extract. D-glucose, imidazole, and RNaseA were 
obtained from BioShop. DNaseI was purchased from Fermentas and Q-Sepharose Hi-Trap 
columns were purchased from GE Biosciences. Through a purchase from BioRad, we obtained 
5mL IMAC columns and Nickel-nitrilotriacetic acid chelate (Ni-NTA) resin was purchased from 
Quiagen. Vivaspin centrifugal ultrafiltration devices were obtained from GE healthcare. The 
crystal screens Top 96, MCSG-1, 2, 3, and 4 were purchased from Microlytic and the screens 
purchased from Molecular Dimensions were Morpheus BN201-1-47, JCSG-Plus BN216-1-40, 
and PACT Premier BN163-1-36. The 96-well INTELLI-PLATEs were purchased from Art 
Robbins Instruments and Crystal Clear sealing tape and IZIT dye was obtained from Hampton 
Research. In addition, 24 well plates were purchased from Crystalgen and the SelenoMet 
Nutrient Mix and Medium Base was purchased from Molecular Dimensions. Any reagents or 
chemicals not listed above were purchased from Sigma-Aldrich. The media Luria-Bertani (LB) 
is commonly used to grow stock cultures after transformations and is also used for general 
culturing of the bacterial strains. LB was made with tryptone (10 g/L), yeast extract (5 g/L), and 
NaCl (10 g/L). Solid LB media when used contained 1% (w/v) agar. A nutrient rich medium, 
termed Super Broth (SB), was used for protein production with bacterial cultures and contained 
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tryptone (32 g/L), yeast (20 g/L), and NaCl (10 g/L). When selecting for target plasmid, 
kanamycin sulfate was added to the media at a final concentration of 50 µg/mL. 
3.2 Bioinformatics Analysis 
Bioinformatics analyses were conducted on the full amino acid sequence of BcsC and all 
sub-constructs prior to the onset and throughout this project to gain a familiarity with the 
hypothesized results and track any changes that may have occurred as databases were modified. 
Briefly, an initial examination of protein characteristics was conducted using the ProtParam 
software (103) that provide information regarding the theoretical isoelectric point (pI), molecular 
weight, molecular extinction coefficient and the number of specific amino acids present in each 
of the protein constructs. This information was crucial for checking protein concentrations, 
optimizing the pH for buffers and other experiments. Additionally Phyre2, a predictive and 
analytical tool for both structural and functional aspects of proteins (104), was used to generate 
sequence homology models with other proteins in the protein databank. The generated 
hypothetical protein databank (PDB) files from Phyre2 were used for figures following graphical 
rendering in PyMOL (105). Multiple sequence alignments of BcsC were generated using protein 
sequences from various organisms via the program BLASTP with the built in iteration PSI-
BLAST (106, 107) and with Clustal omega (108). Meta disorder prediction programs were also 
utilized to identify potential disorder protein regions (109). 
3.3 Protein Constructs and Cloning 
The protein BcsCs TPR domain sequence had been identified in previous bioinformatic 
searches (UniProt P37650) from the sequenced geonome of E. coli K12. Prior to the start of this 
project Phyre2s secondary structure predictor was crossed checked with TPRpred and disorder 
prediction programs to formulate the sequences to create the template for the constructs. Six 
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protein construct derivatives that together cover overlapping portions of the full TPR region of 
BcsC (Figure 6) were codon-optimized to increase the chances of crystallization and to 
investigate ligand/substrate binding in different regions of the protein. For example, certain TPR 
sections may have a stronger affinity for the substrate cellulose and/or certain proteins may stack 
more uniformly for crystallization purposes. These constructs were designed by Dr. Joel Weadge 
and given specific naming designations based on the represented TPR regions, as BcsCTPR1-8, 
BcsCTPR1-11, BcsCTPR1-15, BcsCTPR4-21, BcsCTPR9-21, BcsCTPR12-21, with 1 representing the N-
terminal TPR motif and 21 representing the C-terminal motif. Each construct was subcloned by 
BioBasic into its own pET28a expression vector, which was tailored for protein expression using 
the isopropyl β-D-1-thiogalactopyranoside (IPTG) inducible T7 promoter that is under control of 
the Lac operon operator. IPTG is analogous to lactose in function and when present it removes 
the lac repressor (LacI) from LacO. Transcription of a gene of interest downstream from the T7 
promoter ensues once the cell-encoded T7 RNA polymerase binds. Each expression vector is 
also designed so that transcription/translation results in the inclusion of a His6-tag to the 
respective N or C terminal end (see Table 1 Results section for specific constructs) of the protein 
to facilitate downstream purification and detection steps.  
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Figure 6. Visual Display of BcsCs TPR Constructs. All six protein constructs are illustrated 
with estimated length overlaid on a sample TPR image. Note that this is only a representative 
image and protein constructs and TPR image is not fit to scale.   
 
3.4 General Expression and Purification Strategy 
For the subsequent sections see the attached flow chart to aid in visualization of methods 
(Figure 6). Plasmids containing specific protein constructs with antibiotic resistance were 
individually transformed into CaCl2 E. coli BL-21 competent cells (Novagen) using the standard 
heat shock method (110). Briefly, 5 µL of pET28a plasmid was dispensed into a standard 1.5 mL 
microfuge tube which contained 100 µL of BL-21 competent cells (Novagen) and was incubated 
at approximately 4°C for 30 min. The sample was then heat-shocked at 42°C for approximately 
1.5 min, placed back at 4°C for 5 min before aseptically adding 500 µL pre-warmed (37°C) LB 
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broth and incubating at 37°C for 1 h with shaking at 200 rpm. Transformed cells were plated on 
LB agar (supplemented with 50 µg/mL kanamycin)  and incubated for 14-16 h at 37C. 
 
Figure 7. Flow Chart of Experimental Procedures. This flow chart contains a step-by-step 
outline of the methods section. The flow chart illustrates the streamlined expression and 
purification steps in the middle and emphasizes the extensive optimization of elements to either 
side.  
 
3.4.1 Protein Expression 
Protein expression was conducted in a large-scale fashion with the objective of 
overproducing recombinant protein from each respective BcsC construct transformed into E. coli 
BL21 (pET28) cells. First, initial stock cultures of transformed cells were created by inoculating 
5 mL LB (supplemented with 50 µg/mL kanamycin) with transformed cells followed by 
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incubation at 37C for 15-18 h with shaking (200 rpm). Stock cultures were then used at a ratio 
of 1/50 to inoculate 1 L cultures of SB (supplemented with 50 µg/mL kanamycin). The SB 
cultures were then incubated at 37C with shaking (200 rpm) until the optical density at 600nm 
(OD600) measured between 0.6-0.8 and then IPTG was added to a final concentration of 0.5 mM. 
Following addition of IPTG, induction of protein expression was allowed to continue at 22°C for 
8-16 h (with shaking at 200 rpm) until the cells were harvested by centrifugation (5000 x g for 15 
min at 4°C). The supernatant was discarded, and the collected cell pellets were stored at -20°C 
until needed. 
3.4.2 Protein Purification 
 Several purification steps must be completed to obtain pure protein, as required for 
downstream applications (111). These are outlined below in detail successively in the order 
which they would be performed during a typical purification. 
3.4.2.1 Cell Lysis: Frozen pellets containing the equivalent of 2 L of culture were re-
suspended in 40 mL of lysis buffer (50 mM Tris-HCl pH 8, 300 mM NaCl) to which RNaseA at 
a concentration of 0.0125 mg/mL, DNaseI at a concentration of 0.025mg/mL, and one Pierce 
protease inhibitor tablet was added. The suspension was thawed on a rotating agitator at 4°C 
until the solution was homogenous. Cell lysis was achieved using one pass through a standard 
cell disruptor (Constant Systems TS Series 0.75kW machine Pressure Biosciences) operating at 
17 kpsi sample pressure. The lysate was centrifuged at 20,000 x g for 45 min at 4°C to separate 
the soluble protein from the cellular contaminants (i.e., whole cells and inclusion bodies), the 
supernatant was collected, and the pellet was discarded.  
3.4.2.2 Immobilized metal ion affinity chromatography (IMAC): Approximately 2 mL 
of settled nickel nitrilotriacetic acid (Ni-NTA) resin beads was flushed with approximately 50 
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mL of lysis buffer to remove the ethanol storage buffer. The beads were then suspended in the 
cleared lysate 4°C for 1-2 h on a rotating agitator to facilitate binding of recombinant protein to 
the Ni-NTA resin beads. The resulting solution was then applied to a gravity-flow 50 mL column 
connected to diastolic pump (set at a constant pressure of 1.5 mL/min throughout the procedure) 
and the flow through from the column was collected. The resin remaining in the column, 
containing the His6-tagged proteins of interest, was washed with 50 mL of lysis buffer, followed 
by 50 mL of wash buffer I (50 mM Tris-HCl pH 8, 300 mM NaCl, 20 mM imidazole), and 25 
mL of wash buffer II (50 mM Tris-HCl pH 8, 300mM NaCl, 40 mM imidazole). Finally, the 
column was washed with 25 mL of elution buffer (50 mM Tris-HCl pH 8, 300 mM NaCl, 250 
mM imidazole), which was left to incubate for 5-10 min before collection and storage at 4°C. 
The purpose of this method was to release contaminants in the first 3 washes, while losing only 
minor amounts of the target protein, leaving the final elution consisting of primarily the desired 
recombinant BcsC protein. A standard sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) was conducted to determine protein purity (as outlined below). 
3.4.2.3 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE): 
Samples were prepared by combining 40 L from each of the fractions collected (flow through, 
wash and elution from chromatography columns) with 20 L of 5 times concentrated SDS 
sample buffer (1 mL 2 M Tris-HCl (pH 6.8), 5 mL glycerol, 1.0 g SDS, and mL 0.2% 
Bromophenol blue brought to 10 mL water MQH2O) with 1 mM dithiotreitol (DTT) and heated 
for 5 to 10 min at 90°C. The Mini-PROTEAN tetra cell apparatus (Biorad) housed the gels and 
was filled to the appropriate volume with running buffer (28.8 g glycine, 6.04 g Tris, 2 g SDS, 
and 1.8 L dH20). The first lane was aliquoted with 7 L of precision plus dual colour protein 
standard (BioRad) as a molecular weight reference and each subsequent well had 15 L sample 
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dispensed into it. The only variation of this process was conducted for expression gels that 
involved taking 0.5 mL of culture, pelleting it at 10,000 x g and resuspending in 50 µL of SDS. 
After heating as described above, 20 µL (for T=0; induction), 15 µL (for T=1; ~4 hr), and 10 µL 
(for T=2; ~16 hr) were added to each subsequent well to balance protein levels in favour of a 
more accurate measurement. After the apparatus was closed, the gels were run at 200 V for 45 
min, followed by staining with Coomassie R250 stain solution (2 g Coomassie Brillant Blue 
R250, 500 mL dH20, 400 mL methanol, 100 mL acetic acid (glacial) or transferred to 
nitrocellulose paper for Western blotting analysis. Stained gels were heated in a microwave for 
30 s to speed up the staining process and left to sit on a rocking shaker for 20 to 40 min. 
Afterwards, Commassie R250 stain solution was decanted, de-stain solution (700 mL dH20, 200 
mL methanol, 100 mL acetic acid (glacial) was added, and the process of heating and rocking 
was repeated every 20 min until the desired contrast was achieved. 
3.4.2.4 Western Blots: Western blot transfers were completed using a Trans-Blot 
apparatus (Biorad) filled with transfer buffer (12 mM Tris-HCl, pH 7.5, 96 mM glycine, 20% 
(v/v) methanol) and run at 4°C for 2 h at 100 V. Once transfer onto nitrocellulose was 
completed, the blots were then blocked with blocking buffer (5% (w/v) skim milk powder in 
TBS buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl)) for approximately 1 h. The blots were 
then washed twice in TTBS (20 mM Tris-HCl, pH 7.5, 2 mM NaCl, 0.05% (v/v) Tween) for 7 
min each. Primary antibody (mouse anti-His) was added to a dilution of 1000-fold in 15 mL 
blocking buffer and incubated for 45 min with the blots. After primary incubation, the blots were 
washed in TTBS for 7 min three separate times followed by a 45 min incubation with a 5000-
fold dilution of secondary antibody (alkaline phosphatase conjugated rabbit anti-mouse) in 15 
mL of blocking buffer. Lastly, the blots were washed once more in TTBS. The treated 
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nitrocellulose paper was developed by lightly coating the surface in 5-bromo-5-chloro-3-
indolyphosphate (BCIP) substrate solution (BioShop) and incubated in the dark for 5 to 10 min. 
When the alkaline phosphatase cleaves BCIP on the conjugated secondary antibody, nitroblue 
tetrazolium (NTB) is formed leaving a purple precipitate localized on the His6-tagged target 
protein.  
3.4.2.5 Dialysis: Dialysis was used as the preferred method of buffer exchange for all 
experiments. Dialysis was used to gently remove salt, imidazole, and possible contaminants 
before further purification steps. Collected protein was transferred into dialysis tubing (2 cm of 
dialysis tubing/1 mL of sample) that had been cut to fit the total volume of sample (the average 
was approximately 25 mL) and briefly soaked in distilled water (to increase pliability). After the 
sample was secured by knots in the tubing and clips on the ends, the sample was submerged in 2 
L of dialysis buffer and left at 4°C to gently mix with a stir bar for 1 h. This process required 
replacing the initial dialysis buffer with a new 2 L volume of the same buffer for another 2 to 3 
h. The dialysis buffer consisted of 50 mM Tris-HCl pH 8 for all constructs, excepting       
BcsCTPR 1-11 that required 50 mM Bis-Tris pH 6 for cation exchange experiments.  
3.4.2.6 Ion Exchange: The principle behind the second chromatographic step was to 
separate the protein of interest from contaminant proteins based on charge. Two types of ion 
exchange chromatography exist: anion and cation exchange. Anion exchange uses a positively 
charged resin that attracts negatively charged molecules and was suitable for all protein 
constructs with a pI <7. Cation exchange is the opposite and was more suitable for proteins with 
a pI >7, such as BcsCTPR1-11. The ion exchange was run using a GE Akta Pure FPLC instrument 
with a GE Hi-Trap 5 mL Q-Sepharose anion exchange column. The elution strategy was similar 
to the IMAC procedure, except salt was used instead of imidazole to elute the protein. Protein 
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samples were passed over the column twice at a rate of 5 mL/min to promote binding to the 
resin. The column was then washed in dialysis buffer (50 mM Tris-HCl pH 8 for anion exchange 
and 50 mM Bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane (Bis-Tris) pH 6 for cation 
exchange) at a flow rate of 5mL/min and eluted with a gradient of dialysis buffer and anion 
exchange elution buffer (50 mM Tris-HCl pH 8, 1M NaCl) or cation exchange elution buffer 
(0.5 mM Bis-Tris pH6, 1 M NaCl) for BcsCTPR1-11. The gradient consisted of a gradual shift from 
0% to 100% of cation exchange elution buffer at a rate of 2% per min. Protein constructs eluted 
differently based on their predicted pI, and the progress of elution and collection of fractions was 
monitored at Ab260nm while the fractions were collected in the GE Akta fraction collector. After 
ion exchange was completed, SDS PAGE was conducted using the fractions containing protein 
to verify the presence and purity of the desired protein. 
3.5 Dynamic Light Scattering  
 Polydispersity was analysed using Dynamic Light Scattering (DLS). The polydispersity 
of the protein can indicate how stable the protein is within a particular buffer (112). A low 
polydispersity level indicated that the protein was not aggregated and that the protein was pure. 
A high polydispersity level may have been an indication of contaminant proteins or aggregation 
among even the purest protein, due to unsuitable buffer conditions and/or precipitation. Fractions 
from the anion/cation exchange containing the protein of interest were collected and analysed 
through DLS. The DLS samples were first filtered in microcentrifuge tubes and then dispensed 
into 35 µL wells in duplicate using protein concentrations that ranged from 0.5 mg/mL to 5 
mg/mL and  performed in 50 mM Tris-HCl 150 mM NaCl). Data was collected at room 
temperature (approximately 25C) with 15 acquisitions at 5 s intervals via a DynaPro plate 
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reader (Wyatt Technology, Santa Barbara, CA), and then analyzed using Dynamics software 
(version 7.1).  
3.6 Protein Concentration 
Prior to being placed into crystal plates the protein was first concentrated to maximize the 
chances of crystal formation (111). All protein constructs were collected after ion exchange and 
concentrated using an ultrafiltration apparatus (Centricon) with a 30 kDa molecular weight cut-
off filter; excepting BcsCTPR1-8 that used a 10 kDa filter cutoff. Protein concentration was 
quantified at A280 with the respective extinction co-efficient for each protein construct.  
3.7 Crystal Screening Trials and Optimization 
Crystal screening trials with protein constructs BcsCTPR1-15 and BcsCTPR12-21 were 
completed using several different screens (Morpheus, PACT Premier, JCSG-plus, Top 96, 
MCSG-1, 2, 3, and 4), at a range of different protein concentrations (10-40 mg/mL). The 
Gryphon robot (Art Robbins Instruments) was pre-programmed for different protein to buffer 
ratios (2:1, 1:1, and 1:2) of between 0.2 µL and 0.6 µL of protein in each drop and with 45 µL of 
buffer per well in sitting drop 96-well plates. All sitting drop 96-well plates were incubated at 
18C and 24-well expansion plates were incubated at either 4C, 18C,  or 20C and periodically 
checked by microscopy (Olympus SZX16 Stereomicroscope). Initial crystal screening trials 
yielded crystal hits that were screened for false positives (salt crystals) using ultraviolet light or 
IZIT protein dye. When assessing with ultraviolet light, protein crystal fluorescence due to the 
excitation of aromatic residues (ie. tryptophan) within the protein, whereas salt crystals do not. 
Similarly, when staining with IZIT dye protein crystals absorb the purple dye and turn a dark 
shade of purple or blue, whereas, salt crystals would not. 
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Once a promising crystal hit was discovered, crystallographic expansion trials were 
conducted by recreating the initial crystal growth condition on a larger scale using pre-greased 
hanging drop 24 well crystal plates. Protein and buffer were carefully aliquoted onto 22 mm 
siliconized glass cover slides before each slide was placed on top of each well which contained 
500 L of buffer to generate a hanging-drop crystallization chamber. A range of different ratios 
were used as the volume (in µL) of protein to buffer was varied from 4:1, 4:2, 3:2, 2:2, 2:1, 2:2, 
1:2, 2:3, 2:4 and 1:4 depending on the trial. The preparation of buffers for the crystal conditions 
involved creating a stock solution that was balanced to the proper pH and then diluted to the 
proper concentration, followed by the addition of salts, and/or additives such as PEG or glycerol. 
For example, optimization of the MCSG-3 G12 condition (0.1 M sodium acetate pH 4.6, 2 M 
sodium formate) involved varying the buffer (sodium acetate) concentration in one row while 
holding the precipitant (sodium formate) constant, then varying the precipitant concentration in 
another row while holding the buffer concentration constant. Following this, variations of both 
precipitant and buffer concentration not yet attempted were prepared in a grid style screening. 
The final pH of the condition was always checked against the pH of the premade screen from 
which it was derived from to ensure consistency.  
A variety of additives (glycerol, DMSO, and ethylene glycol) were used in conditions 
that already produced crystals, with the hopes of refining the crystals, at a variety of different 
concentrations (1.25, 2.5, 5, and 10% (v/v)). In addition, some trials were completed with the 
substrates D-glucose and cellobiose pre-incubated with the protein in co-crystallization efforts. 
Furthermore, to increase the chances of crystallization, a crystal streak seeding technique was 
used to introduce nucleation sites (113). This technique was used in combination with additives, 
as well as substrates, with the intention of optimizing pre-existing conditions. Crystal seeding 
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can be effective when placing crystal seeds into a supersaturated zone, termed the metastable 
zone, because growth occurs readily in this zone, but nucleation points do not form and hence the 
introduction of nucleation points can effectively allow crystals to grow (Figure 8) (113). 
Crystallization without seeding involves creating a condition that begins in the supersaturated 
labile zone (nucleation points can form) followed by the supersaturated zone to promote growth. 
However, this process can yield crystals that are difficult to harvest due to precipitation 
surrounding the crystals (113). The common concern with crystal seeding is that an abundance of 
nuclei will be placed into the supersaturated solution and yield masses of crystals unsuitable for 
diffraction analysis (ie. typically too small) (113). When this was observed for seeding in our 
crystal growth experiments, a dilution series was created from the seed stock and a more suitable 
fold dilution was used (102 or 103). 
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Figure 8. Phase Diagram for Crystallization. The y-axis represents the protein concentration 
and the x-axis represents salt or precipitant concentration. The stable, undersaturated zone 
usually represents a clear well with no crystallization. The metastable supersaturated zone can 
develop nuclei into crystals, yet nucleation points do not form here. The labile supersaturated 
zone can both form nucleation points and support crystal development. The supersaturated 
precipitation zone is often a region that contains precipitation and can support crystal growth, 
though may not yield easily harvestable crystals (adapted from 94). 
 
To facilitate uncovering optimal screening conditions in a limited time frame for this 
thesis, proteins BcsCTPR 1-11, BcsCTPR 9-21, and BcsCTPR 12-21 were sent to the Hauptman-
Woodward Medical Research Institute (HWI) for high-throughput crystallization screening. This 
facility  performed 1,536-well microassay plate screenings for the BcsC protein constructs using 
a microbatch-under-oil technique (114). HWI used automated liquid handling to facilitate set-up 
of the crystal screens and each well was imaged before adding the protein solution, after addition 
of the protein solution, followed by imaging at the one day, one week, two week, three week, 
four and six week timepoints. Only the final well images are accompanied by Second Order 
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Nonlinear Optical Imaging of Chiral Crystals (SONICC) images from a Formulatrix Rock 
Imager 1000 designed to determine if an object (as small as <1 µM) was crystalline (115) and 
images from two-photon excited ultraviolet fluorescence (TPE-UVF) to further interrogate if it is 
protein (116). HWI screening with BcsC constructs was performed twice. For the first 
experiment, protein samples were prepared the night before screening, shipped express 
overnight, and stored at 4°C before screening, while the second trial involved freezing the 
samples at -80°C and shipping overnight express on dry ice in an attempt to preserve protein 
quality. 
3.8 X-ray Diffraction 
Crystals that were selected for X-ray diffraction were analyzed either at the University of 
Waterloo or the Canadian Light Source. Prior to analysis, crystals were looped using an 
appropriate size loop (Mitegen) and soaked in a cryo-protectant solution consisting of the mother 
liquor (condition in which the crystal was formed) supplemented with either 33% (v/v) glycerol 
or ethylene glycol (for crystals from Top 96 A1: 0.2 M MgCl, 0.1 M Tris-HCl pH 8.5, 30% (w/v) 
PEG 4000), or 6 M sodium formate (for crystals from condition MCSG-3 G12: 0.1 M sodium 
acetate pH 4.6, 2 M sodium formate) for 20-60 s. The crystals were vitrified in liquid nitrogen 
and stored in liquid nitrogen until diffraction was performed. Full crystal data sets were collected 
using synchrotron radiation on the 08B1-1 beamline at the Canadian Macromolecular 
Crystallography Facility (Canadian Light Source, Saskatoon) using a CCEL MD2 
microdiffractometer and MarMosaic mx300 CCD X-ray detector. Typical datasets consisted of 
360 images at 1 oscillations and an exposure time of 0.2 s per image at the CLS. The data were 
integrated, reduced and scaled using AutoProcess on MxLive (117). 
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3.9 Molecular Replacement and Model Building 
 Molecular replacement was attempted to determine the phases of the collected data. PDB 
files from previously solved structures of BcsCTPR1-6 (PDB ID: 5xw7) and AlgK (PDB ID: 3e4b), 
as well as structures with at least 25% amino acid sequence identity to BcsCTPR1-15 identified 
with Phrye2 and BLASTP searches were used as possible replacement models. These 
replacement models were prepared by using the Sculptor (118) of PDB tools program in the 
Phenix suite (119) to edit the PDB files to not contain heteroatoms and consist of a single 
polypeptide chain. In later steps, further trimming of the PDB files to alanine traces of the model 
was also accomplished with Sculptor. Molecular replacement with each of these templates was 
then attempted with the MRage and/or Phaser modules (120) of the Phenix suite. As an 
alternative, the automated molecular replacement was also attempted online through the CCP4 
online interface (121) with the BALBES (122), MrBump (123), and MoRDa (124) programs. 
Following molecular replacement by these methods, model building was attempted with 
Autobuild in the Phenix suite through iterative variations consisting of different rounds of 
refinement, building helices and strands and morphing the input model into density features. 
3.10 Selenomethionine Expression 
 As an alternative route to solving the structure with molecular replacement, 
selenomethionine (SeMet) derivatives of the protein were generated to employ anamolous 
dispersion techniques for structure determination. SeMet media was prepared by  mixing 21.6 g 
SeMet Medium Base with 1 L of ddH2O and autoclaving for sterility. Prior to use of the media, 
kanamycin was added to a final concentration of 50 g/mL along with Nutrient solution (5.1 g 
SeMet Nutrient mix) premixed in 50 mL of MQH2O and sterilized by passing through a 22 m 
filter (VWR)  and a final 40 µL concentration of analytical grade L-(+)-SeMet. Prior to 
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inoculation of the SeMet media, a 50 mL stock culture grown in LB media (as opposed to 20 mL 
used for native expression) was pelleted by centrifugation (4000 x g, 20 min, 4°C) and carefully 
rinsed once with MQH2O to eliminate traces of methionine. The culture pellet was resuspended 
in a minimal volume of sterile SeMet media then aseptically added back to the larger 1 L of 
SeMet growth medium. SeMet expression of protein construct (only BcsCTPR 1-15 was expressed 
thus far) was then conducted under the same conditions as native expression (22°C, 200 rpm). 
When the culture reached an OD600 of 0.6, IPTG was added to a final concentration of 1 mM to 
induce expression of the target protein, and the culture was allowed to incubate for an additional 
16-18 h, followed by centrifugation at 5000 x g and the pellet stored at -20°C until needed. All 
techniques for protein purification were the same as outlined in previous sections. SeMet 
prepared versions of BcsTPR1-15 required anion exchange purification after IMAC and dialysis. 
The BcsTPR1-15 SeMet crystal expansion plates were set up in a condition containing 0.1 M 
sodium acetate pH 4.6, 2 M sodium formate at a concentration of 25 and 28 mg/mL. 
3.11 Small angle X-ray scattering (SAXS) 
SAXS data was collected at the SIBYLS beamline (12.3.1) at the Advanced Light Source 
part of the Lawrence Berkeley National Laboratory (125). The X-ray wavelength used was 1.0 Å 
with a flux of 1013 photons per second and the sample-to-detector distance set to 1.5 m. 
Scattering images were collected using a Pilatus 2 M detector every 0.3 s, with a total of 33 
images per sample. All sampling was performed at 10°C and data was processed as described 
(126). Briefly, a collection of three separate protein concentrations (1, 5, and 10 mg/mL) was 
used to correct for concentration-dependent behaviour and two protein-free buffer samples were 
collected, for every 3 sample concentrations, to reduce error in subtraction (127, 128). Every 
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collected image was circularly integrated then normalized for beam intensity to generate a 1-
dimensional scattering profile (127, 128). 
The 1-dimensional scattering profile of each respective protein sample was buffer-
subtracted by the two respective buffers to produce two sets of buffer-subtracted sample profiles 
(127, 128). Scattering profiles were examined for radiation damage by sequentially averaging 
them together until radiation damage effects were noticeably altering the scattering curve (127, 
128). Averaging was performed using the web-based software program from the SIBYLS 
website called Frameslice (129). The program SCÅTTER (130) was used to compute the radius 
of gyration (Rg), Rc, P, Q, and volume parameters, which can be used for corroborating data 
with current knowledge about the target protein (ie. validity checking). The GNOM function 
(131) was used in the program PRIMUS (132) to compute the pair distribution (P(r) function) 
and the maximum distance of the molecule (Dmax) was estimated using the P(r) function.  
Imaging was conducted with the program GASBOR (133) through the online data 
analysis server ATSAS 2.8.4 (https://www.embl-hamburg.de/biosaxs/atsas-online/) (134), which 
produced models consisting of dummy residues. GASBOR was also used in conjunction with 
DAMAVER (135) through the SIBYLS beamline website (http://sibyls.als.lbl.gov/)  for SAXS 
applications to analyse the data. The resultant PDB file produced by DAMAVER was opened in 
PyMOL and fitted with an alanine model of the PDB file (5xw7) from the solved structure of 
BcsCTPR 1-6 using SASpy (136). 
 
 
 
47 
 
4. Results 
4.1 Bioinformatic Analyses: 
A thorough bioinformatics investigation of the BcsC constructs was conducted using 
several different programs and was utilized throughout all stages of research. ProtParam (103), a 
quick and simple tool used, was important for the planning of wet lab experimentation as it 
provided the molecular weights, extinction coefficients, the theoretical pIs, and other relevant 
information (Table 1) for calculating protein concentrations, following molecular mass on 
purification gels and aiding in decisions for purification steps (eg. cation exchange for     
BcsCTPR 1-11. Of the constructs generated and analyzed, BcsCTPR 4-21 was the largest and 
encompassed the majority of the TPR region, while BcsCTPR 1-8 was the smallest, with only the 
N-terminal TPR regions included. This range of constructs provided us with a panel of TPR 
regions and attributes that led to improving our chances of producing soluble purified protein. 
For example, from the instability index analysis (ProtParam), BcsCTPR 1-15 is predicted to be the 
most unstable by nearly 2 units and rated both BcsCTPR 12-21and BcsCTPR 4-21 the most stable. 
However, this may not be significant, as instability index predicts that only proteins over a score 
of 40 are considered unstable and all BcsC constructs fall within a reasonable range of this limit 
(103).  
Clustal omega, a bioinformatics tool, was used to identify amino acid conservation 
between BcsC constructs and other similar proteins through a manual input interface. Due to 
homology, the primary proteins of interest were AlgK and BcsC from Enterobacter CJF-002. 
The comparison matrix for AlgK is presented from the alignments in Table 2. When examining 
the sequence identities between AlgK and BcsC constructs, little variation is found. The full-
length construct (BcsCTPR 1-21) has the exact percentage as BcsCTPR 4-21 (24.46%) and BcsCTPR 1-15 
48 
 
has the lowest sequence identity (22.51%). The highest sequence identity is BcsCTPR 12-21 
(25.93%) and the rest of the constructs range between. These percentages may not be high 
enough to use the AlgK PDB file for molecular replacement, as the recommended search criteria 
for sequence similarity 25-35% (137). The sequence identity between the full length TPR 
domain of BcsC from Enterobacter CJF-002 and E. coli K12 was 72.38, whereas, the individual 
construct homology (presented in Table 3) ranged between 71 and 73% identity. These results 
are promising and provide relevance towards SAXS and molecular replacement modelling, for 
example, a SAXS envelope can be merged with the PDB file from Enterobacter CJF-002 in 
PyMOL that may help signify the validity of the SAXS data. Furthermore, the high sequence 
identity may provide a strong background to build a molecular replacement model using the 
phase information from Enterobacter CJF-002. 
A number of programs were instrumental in aiding our structural work and subsequent 
hypothesis design. The programs Phyre2 and PSI-BLAST were used to complement each other in 
identifying potential homologs for BcsC. PSI-BLAST, a secondary program that builds and 
refines initial search alignments conducted by BLAST (106, 107), found several homologous 
sequences and the top 5 results were recorded for later structural modeling (Table 4). Phyre2 was 
used to identify homologs (based on amino acid sequence and overall fold) and generate 
structural models (as Protein data bank (PDB) files) that were compatible with several programs 
used for tertiary structure modeling/imaging. For example, PyMOL and Coot (138) were used to 
visualize hypothetical models of the entire TPR domain (BcsCTPR 1-21) and 6 of the BcsC protein 
constructs (Figures 9-15) to visualize individual TPR regions and map possible key conserved 
residues. The top 5 results of homologous proteins identified by Phyre2 are presented in Table 5, 
each individual result represents one protein that has predicted homology to BcsC with a specific 
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corresponding PDB file (template number) and title of each respective crystal structure. The high 
alignment coverage is due to amino acid homology because the percent identity is 15% or lower 
for all models. The structures of these proteins and the BcsC-based models thereof (eg. threaded 
structural models), were used in downstream SAXS and molecular replacement analyses to 
differing degrees of success (as outlined in subsequent sections).  
The program TPRpred (https://toolkit.tuebingen.mpg.de/#/tools/tprpred) (139) was used 
to predict the number and location of TPRs within the BcsC TPR domain. Prior to this, an 
analysis of the full length BcsC TPR domain in the secondary structure prediction section of 
Phyre2 indicated strong alpha helical character up to approximately residue 790 (See Appendix 
A1) and from a visual examination of this section counted over 40 alpha helical regions. 
Accordingly, the BcsC construct designation was extended to allow for the possibility of 21 TPR 
segments. When the full length BcsC TPR sequence was inputted in TPRpred, 18 TPRs were 
predicted (Table 6), hence, it is not known the exact number of BcsCs TPR regions, but it was 
believed to be between 18-21 TPRs. 
The final bioinformatical analysis was conducted using disorder prediction software. 
Disorder prediction methods are designed to help find boundaries of ordered protein domains 
and regions of disorder, to allow the experimental study of each domain separately (109).  
Numerous disorder prediction software exists as well as tools that combine results from many 
different individual methods. Using meta predictions may lead to increased accuracy (109) and 
the programs metaPrDos and DisMeta were utilized for disorder prediction. Results from the 
disorder prediction indicate considerable disorder at each terminus of every construct. The 
disorder prediction of BcsCTPR 4-21 presented in Figure 16 illustrates a stretch of 7 residues that 
appear disordered in addition to the disordered termini. Interestingly, some other constructs 
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contain this amino acid series yet do not show disorder above the 5% false positive confidence, 
so this may not be significant as the difference is minimal. 
Table 1. ProtParam Protein Features for BcsC Constructs 
BcsC TPR 
Construct 
Designation 
TPR 1-8 TPR 1-11 TPR 1-15 TPR 4-21 TPR 9-21 TPR 12-21 
Amino Acids 
(Start and End) 
318 
(24-294) 
434 
(24-410) 
582 
(24-558) 
675 
(145-820) 
471 
(349-820) 
361 
(459-820) 
Molecular 
Weight 
34044.03 47137.53 63926.10 73944.04 52238.73 39858.08 
Extinction 
coefficient 
(M-1 cm-1, at 
280 nm 
measured in 
water) 
21430 41370 69330 90300 67840 53400 
Theoretical pI 6.41 7.99 6.67 5.83 5.64 5.41 
Instability 
index 
40.31 41.02 44.26 39.81 42.94 39.58 
Methionine 
residues 
4 6 8 11 8 6 
Cysteine 
residues 
0 0 0 0 0 0 
Tryptophan 
residues 
2 4 8 11 8 7 
His6-tag location N-terminal N-terminal N-terminal C-terminal C-terminal C-terminal 
*The E. coli K12 BcsC amino acid sequence can be found in Appendix Section A1. The values 
were calculated with the inclusion of His6-tags. 
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A)                                                                                B)
 
Figure 9. Phyre2 Predicted Structural Model of BcsCTPR 1-21. Phyre2 model of BcsCTPR 1-21 
(based on PDB: 4BUJ 14% identity) in its native state observed in one superhelical conformation 
displayed at 2 separate angles (A, & B). Each helix-turn-helix (TPR) is coloured from N-terminal 
(red) to C-terminal (blue) for distinction. All images were rendered in PyMOL. 
 
 
A)                                                                                B) 
 
Figure 10. Phyre2 Predicted Structural Model of BcsCTPR 1-8. Phyre2 model of BcsCTPR 1-8 
(based on PDB: 4HNX 11% identity) in its native state observed in one superhelical 
conformation displayed at 2 separate angles (A, & B). Each helix-turn-helix (TPR) is coloured 
from N-terminal (red) to C-terminal (blue) for distinction. All images were rendered in PyMOL. 
90◦ 
90◦ 
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A)                                                                                B) 
  
Figure 11. Phyre2 Predicted Structural Model of BcsCTPR 1-11. Phyre2 model of BcsCTPR 1-11 
(based on PDB: 1W3B 13% identity) in its native state observed in one superhelical 
conformation displayed at 2 separate angles (A, & B). Each helix-turn-helix (TPR) is coloured 
from N-terminal (red) to C-terminal (blue) for distinction. All images were rendered in PyMOL. 
A)                                                                                B) 
 
 Figure 12. Phyre2 Predicted Structural Model of BcsCTPR 1-15. Phyre2 model of BcsCTPR 1-15 
(based on PDB: 5NNR 12% identity) in its native state observed in one superhelical 
conformation displayed at 2 separate angles (A, & B). Each helix-turn-helix (TPR) is coloured 
from N-terminal (red) to C-terminal (blue) for distinction. All images were rendered in PyMOL. 
 
 
 
 
 
90◦ 
90◦ 
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A)                                                                                B) 
 
 
 Figure 13. Phyre2 Predicted Structural Model of BcsCTPR 4-21. Phyre2 model of BcsCTPR 4-21 
(based on PDB: 4BUJ 14% identity) in its native state observed in one superhelical conformation 
displayed at 2 separate angles (A, & B). Each helix-turn-helix (TPR) is coloured from N-terminal 
(red) to C-terminal (blue) for distinction. All images were rendered in PyMOL. 
A)                                                                                B) 
  
 Figure 14. Phyre2 Predicted Structural Model of BcsCTPR 9-21. Phyre2 model of BcsCTPR 9-21 
(based on PDB: 4UZY 14% identity) in its native state observed in one superhelical 
conformation displayed at 2 separate angles (A, & B). Each helix-turn-helix (TPR) is coloured 
from N-terminal (red) to C-terminal (blue) for distinction. All images were rendered in PyMOL. 
 
 
 
90◦ 
90◦ 
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A)                                                                                B) 
 
 Figure 15. Phyre2 Predicted Structural Model of BcsCTPR 12-21. Phyre2 model of BcsCTPR 12-21 
(based on PDB: 4HNX 11% identity) in its native state observed in one superhelical 
conformation displayed at 2 separate angles (A, & B). Each helix-turn-helix (TPR) is coloured 
from N-terminal (red) to C-terminal (blue) for distinction. All images were rendered in PyMOL. 
Table 2. BcsCs Percent Identity with AlgK 
Protein Name Sequence Identity % 
AlgK 100.00 
BcsCTPR 1-21 (Full Length TPR Domain) 24.46 
BcsCTPR 4-21 24.46 
BcsCTPR 9-21 23.96 
BcsCTPR 12-21 25.93 
BcsCTPR 1-8 24.49 
BcsCTPR 1-11 22.89 
BcsCTPR 1-15 22.51 
* Clustal Omega generated percent identity matrix based on amino acid sequences was used to 
construct this table 
Table 3. BcsC Construct Percent Identity to Enterobacter CJF-002 BcsC TPR Domain 
Protein Name Sequence Identity % 
Enterobacter CJF-002 BcsC 100.00 
BcsCTPR 1-21 (Full Length TPR Domain) 72.38 
BcsCTPR 4-21 71.32 
BcsCTPR 9-21 72.92 
BcsCTPR 12-21 71.03 
BcsCTPR 1-8 71.75 
BcsCTPR 1-11 73.32 
BcsCTPR 1-15 72.19 
* Clustal Omega generated percent identity matrix based on amino acid sequences was used to 
construct this table 
90◦ 
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Table 4. Top 5 BLAST Results with PSI-BLAST for BcsCTPR 1-21 
PDB Title Max 
Score* 
Total 
Score 
Query 
coverage 
% I.D. PDB I.D. 
Crystal structure of the flexible 
tandem repeat domain of bacterial 
cellulose synthase subunit C 
362 362 42% 72 5XW7_A 
Crystal Structure of an 8 Repeat 
Consensus TPR Superhelix 
63.9 208 37% 32 2FO7_A 
Design of Stable Alpha-Helical Arrays 
from An Idealized TPR Motif 
57.8 106 28% 31 1NA0_A 
Crystal structure of CTPR3Y3 47.8 126 28% 30 2WQH_A 
Designed TPR Module (Ctpr390) In 
Complex with Its Peptide-Ligand 
(Hsp90 Peptide) 
47.4 128 33% 29 3KD7_A 
* Order is ranked by the maximum score and the total score is presented along with the query 
coverage, percent identity and the PDB identification number. 
Table 5. Top 5 Phyre2 Predicted Homology Results for BcsCTPR 1-21  
PDB Coverage Confidence % 
i.d. 
PDB Molecule PDB Title 
1. c5nnrD 99% 100.0 12 N-terminal 
acetyltransferase-like 
protein 
Structure of 
naa15/naa10 bound 
to hypk-thb 
2. c4bujF 99% 100.0 15 Superkiller protein 3 Crystal structure of 
the s. cerevisiae 
ski2-3-8 complex 
3. c6c95A 99% 100.0 11 N-alpha-
acetyltransferase 15, 
nata auxiliary 
The human nata 
(naa10/naa15) 
amino-terminal 
acetyltransferase 
complex2 bound to 
hypk 
4. c4hnxA 99% 100.0 10 N-terminal 
acetyltransferase a 
complex subunit nat1 
The nata 
acetyltransferase 
complex bound to 
ppgpp 
5. c4uzyA 98% 100.0 11 Flagellar associated 
protein 
Crystal structure of 
the Chlamydomonas 
ift70 and ift52 
complex 
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Table 6. TPRpred Results from BcsC Full Length TPR Domain. 
TPR 
repeat 
number 
Begin Alignment Ending Amino 
Acid Residue 
Number 
1 5 QQQLLEQVRLGEATHREDLVQQSLYRLELIDPNN 38 
2 39 PDVVAARFRSLLRQGDIDGAQKQLDRLSQLAPSS 72 
3 82 MLLSTPDGRQALQQARLQATTGHAEEAVASYNKL 115 
4 124 DIAVEYWSTVAKIPARRGEAINQLKRINADAPGN 157 
5 158 TGLQNNLALLLFSSDRRDEGFAVLEQMAKSNAGR 191 
6 246 AFRARAQGLAAVDSGMAGKAIPELQQAVRANPKD 279 
7 280 SEALGALGQAYSQKGDRANAVANLEKALALDPHS 313 
8 328 YWLAIQQGDAALKANNPDRAERLFQQARNVDNTD 361 
9 362 SYAVLGLGDVAMARKDYPAAERYYQQTLRMDSGN 395 
10 396 TNAVRGLANIYRQQSPEKAEAFIASLSASQRRSI 429 
11 438 NDRLAQQAEALENQGKWAQAAALQRQRLALDPGS 471 
12 472 VWITYRLSQDLWQAGQRSQADTLMRNLAQQKSND 505 
13 506 PEQVYAYGLYLSGHDQDRAALAHINSLPRAQWNS 539 
14 544 LVNRLQSDQVLETANRLRESGKEAEAEAMLRQQP 577 
15 580 TRIDLTLADWAQQRRDYTAARAAYQNVLTREPAN 613 
16 614 ADAILGLTEVDIAAGDKAAARSQLAKLPATDNAS 647 
17 648 LNTQRRVALAQAQLGDTAAAQRTFNKLIPQAKSQ 681 
18 688 AMVLRDGAKFEAQAGDPTQALETYKDAMVASGVT 721 
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Figure 16. meta PrDos Disorder Prediction Results of BcsCTPR 4-21. The top panel contains a 
numbered amino acid sequence of BcsCTPR 4-21 where the red letters indicate potential disordered 
residues. The bottom graph is the disorder profile plot where the y-axis represents disorder 
tendency and the x-axis is the BcsCTPR 4-21 residue number. The purple line represents the average 
of multiple disorder prediction programs. The other programs are signified by a mixture of 
different coloured lines. 
 
4.2 Protein Expression and Purification 
4.2.1 Protein Expression 
The E. coli cells containing the BcsC optimized genes all followed a similar trend during 
protein expression. Numerous trials of protein expression were conducted in previous 
experiments over a range of IPTG concentrations and induction temperatures (4°C, 16°C, 22°C 
and 37°C; this thesis work and Anderson & Weadge, unpublished work). The optimal 
temperature was found to be 22°C with an IPTG concentration between 0.5 and 1 mM. The 
duration of the protein expression phase after induction with IPTG was assessed between 4 and 
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16 hours and negligible differences in downstream protein yields or solubility were noted. This 
trend is exemplified by comparing BcsCTPR 4-21 (Figure 17; ~74.1 kDa), BcsCTPR 1-11 (Figure 18; 
47.3 kDa), and BcsCTPR 1-15 (Figure 19; 64 kDa) expressed fractions in the 4 h post-induction 
(lane 3 in each of the figures) and 16 h post-induction (lane 4 in each of the figures) samples. 
You will have to note, that although lanes for expression of BcsCTPR 1-8, BcsCTPR 9-21, and 
BcsCTPR 12-21 are not depicted in Figures 20, 21, and 22 respectively, they followed a similar 
trend to BcsCTPR 1-15 (Figure 19). The only exception to this trend is noted with the respective 
protein band for BcsCTPR 4-21 at the 16 h mark being less than the 4 h mark. Previous studies have 
identified that in some cases, less soluble protein was produced due to the formation of inclusion 
bodies, through aggregation, within E.coli expression systems at molecular weights of over ~60 
kDa (140). In these cases, a longer expression may allow protein to degrade, thus, lowering the 
amount and the quality of the soluble protein yield. Despite the degradation and/or aggregation 
that may be associated with this construct (if any), the total amount of soluble protein gained 
from the extra hours of expression was deemed to out-weigh any amount lost.  
The largest protein yields after secondary purification were with BcsCTPR 1-11 and BcsCTPR 12-21 
(Table 7). Proteins over ~60 kDa may exhibit less successful expression of soluble protein in E. 
coli (140) and BcsCTPR 4-21 and BcsCTPR 1-15 are both over 60 kDa, while BcsCTPR 9-21 (~52.4) is 
fairly close to this threshold. While size may play a factor, it is unclear precisely why protein 
expression was different among constructs and could also entail better expression or binding to 
the purification columns under the conditions used. Regardless, most of the constructs yielded 
protein amounts that were amenable to downstream analyses, so once these concentrations were 
achieved with a standard protocol, further optimization was not pursued. 
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Figure 17. SDS-PAGE Protein Expression and Purification of BcsCTPR 4-21. SDS-PAGE 
analysis (12% (v/v)) of BcsCTPR 4-21 expression of 1 L cultures incubated at 22°C and 200 rpm 
shaking. Lane 1, molecular-weight markers (kDa); lane 2, before induction sample; lane 3, 
expression time 4 h sample; lane 4 expression time 16 h; lane 5, Ni-NTA column unbound 
lysate; lane 6, wash with lysis buffer (no imidazole); lane 7, wash 1 (20 mM imidazole); lane 8, 
wash 2 (40 mM imidazole); lane 9, elution buffer (250 mM imidazole); lane 10, elution fraction 
from anion exchange chromatography column. 
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Figure 18. SDS-PAGE Protein Expression and Purification of BcsCTPR 1-11. SDS-PAGE 
analysis (12% (v/v)) of BcsCTPR 1-11 expression of 1 L cultures incubated at 22°C and 200 rpm 
shaking, Ni-NTA purification fractions, and a concentrated ion exchange chromatography 
sample. Lane 1, molecular-weight markers (kDa); lane 2, expression induction time 0 sample; 
lane 3, expression time 4 h sample; lane 4 expression time 16 h; lane 5, Ni-NTA column 
unbound lysate; lane 6, wash with lysis buffer (no imidazole); lane 7, wash 1 (20 mM 
imidazole); lane 8, wash 2 (40 mM imidazole); lane 9, elution buffer (250 mM imidazole); lane 
10, sample of concentrated fractions pooled following cation exchange chromatography.  
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Figure 19. SDS-PAGE Protein Expression and Purification of BcsCTPR 1-15. SDS-PAGE 
analysis (12% (v/v)) of BcsCTPR 4-21 expression of 1 L cultures incubated at 22°C and 200 rpm 
shaking, Ni-NTA purification fractions, and anion exchange flow through. Lane 1, molecular-
weight markers (kDa); lane 2, expression induction time 0 sample; lane 3, expression time 4 h 
sample; lane 4 expression time 16 h; lane 5, Ni-NTA column unbound lysate; lane 6, wash with 
lysis buffer (no imidazole); lane 7, wash 1 (20 mM imidazole); lane 8, wash 2 (40 mM 
imidazole); lane 9, elution buffer (250 mM imidazole); lane 10, flow through from anion 
exchange chromatography column. 
 
Figure 20. SDS-PAGE Purification of BcsCTPR 1-8. SDS-PAGE analysis (12% (v/v)) of 
BcsCTPR 1-8 Ni-NTA purification fractions. Lane 1, molecular-weight markers (kDa); lane 2, Ni-
NTA column unbound lysate; lane 3, wash with lysis buffer (no imidazole); lane 4, wash 1 (20 
mM imidazole); lane 5, wash 2 (40 mM imidazole); lanes 6-8, elution buffer (250 mM 
imidazole). 
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 Figure 21. SDS-PAGE Purification of BcsCTPR 9-21. SDS-PAGE analysis (12% (v/v)) of 
BcsCTPR 9-21 Ni-NTA purification fractions, an anion exchange chromatography fraction and a 
concentrated sample of anion fractions. Lane 1, molecular-weight markers (kDa); lane 2, Ni-
NTA column unbound lysate; lane 3, wash with lysis buffer (no imidazole); lane 4, wash 1 (20 
mM imidazole); lane 5, wash 2 (40 mM imidazole); lanes 6, elution buffer (250 mM imidazole); 
lane 7, anion exchange elution fraction; lane 8, concentrated sample of anion exchange fractions. 
 
4.2.2 Immobilized Metal Affinity Chromatography 
 After protein expression, IMAC purification was utilized to isolate the his6-tagged 
recombinant proteins for all constructs. The only construct that was not be purified past IMAC 
was BcsCTPR 1-8 due to greater difficulties with degradation compared to most other constructs. 
This construct was not pursued further as this TPR region was already covered with other protein 
constructs (BcsCTPR 1-11, BcsCTPR 1-15) that behaved noticeably better during purification.  
Purification of all constructs followed a common route that involved loading lysate onto the 
column in the absence of imidazole and then gradually increasing the presence of this molecule 
through the washing steps (up to 40mM) to remove background contaminants and then finally 
eluting in 250 mM imidazole. SDS PAGE images of BcsCTPR 4-21, BcsCTPR 1-11, and BcsCTPR 1-15 
(Figures 17, 18, and 19; lanes 5-9) as well as BcsCTPR 1-8, BcsCTPR 9-21 (Figures 20 and 21; lanes 
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5-8) and BcsCTPR 12-21 (Figures 22; lanes 3-10) contain typical IMAC purification samples. 
Although some protein was lost in the wash steps the majority of the protein was contained in the 
elutions across all protein constructs as indicated through strong bands focused around the 
appropriate molecular weights (BcsCTPR 4-21 74.1 kDa~, BcsCTPR 1-11 ~43.3 kDa BcsCTPR 1-15 ~64 
kDa, BcsCTPR 1-8 ~34.2 kDa, BcsCTPR 9-21 ~52.4 kDa, and BcsCTPR 12-21 ~40 kDa, respectively). A 
significant amount of contaminating protein (as seen by additional bands on the SDS-PAGE 
gels) was noted for BcsCTPR 1-8 (Figure 20; lanes 6-8) and BcsCTPR 9-21(Figure 21; lane 6), 
thereby, prompting a definite need for secondary purification with these two constructs. In 
contrast, the BcsCTPR 12-21 elutions (Figure 22; Lanes 6-10) contained significantly less 
contamination, but secondary purification was still performed (outlined below) to further remove 
contaminants even for this construct on a routine basis so that downstream analyses would have 
the purest protein possible. 
 
Figure 22. SDS-PAGE Purification of BcsCTPR 12-21. SDS-PAGE analysis (12% (v/v)) of 
BcsCTPR 12-21 Ni-NTA purification fractions. Lane 1, molecular-weight markers (kDa); lane 2, 
Ni-NTA column unbound lysate; lane 3, wash with lysis buffer (no imidazole); lane 4, wash 1 
(20 mM imidazole); lane 5, wash 2 (40 mM imidazole); lanes 6-10, elution buffer (250 mM 
imidazole). 
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4.2.3 Ion Exchange Chromatography 
 Following pooling of elutions, dialysis to remove salts and concentration of protein 
constructs, they were subjected to ion exchange chromatograph. Ion exchange profiles were 
similar for all constructs tested and a typical profile is displayed in Figure 23 for BcsCTPR 9-21. 
The ion exchange profile is signified by a large blue “bump” that represents the protein being 
passed over the ion column numerous times to facilitate ample time for binding of BcsC to the 
ion column. This is followed by a large dip in the blue line that represents buffer containing no 
salt removing protein that did not bind to the column (some contaminations are lost). Elution of 
target proteins from the column were observed as a second peak in the profile and the apex for 
this peak for all constructs tested is presented in Table 8 as a comparison of elution 
times/volumes. As a companion to these profiles to judge purity and the presence of the desired 
protein construct, SDS-PAGE analysis of the elution fractions was also performed (example 
elutions for BcsCTPR 12-21 and BcsCTPR 9-21depicted in Figure 24). A comparison of the ion 
exchange elutions to the earlier IMAC elutions (ie. Figure X and Y for BcsCTPR 12-21 and 
BcsCTPR 9-21, respectively) clearly indicated that ion exchange chromatography greatly increased 
the protein purity. This was true for all constructs where the purity of BcsCTPR 4-21 (Figure 17; 
lane 10) BcsCTPR 1-11 (Figure 18; lane 10) and BcsCTPR 1-15 (Figure 19; lane 10) was better 
compared to the previous lane (IMAC elution) in all of the respective figures. 
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Figure 23. Example Ion Exchange Purification Profile of BcsCTPR 9-21. Monitoring of elution 
from the anion exchange column for the BcsCTPR 9-21 construct was accomplished by recording 
the absorbance at 305 nm (Blue line) in conjunction with elution using an increasing 
concentration of NaCl (represented by the green line). The black arrow denotes the elution peak 
for BcsCTPR 9-21 that was collected and further analyzed via SDS PAGE. This chromatogram is a 
typical profile for each of the BcsC constructs tested through Ion Exchange Chromatography. 
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 Figure 24. Anion Exchange Purification of BcsCTPR 12-21 and BcsCTPR 9-21.SDS-PAGE 
analysis (12% (v/v)) of BcsCTPR 12-21 and BcsCTPR 9-21 anion exchange chromatography fractions. 
Lane 1, molecular-weight markers (kDa); lanes 2-5, BcsCTPR 12-21 anion exchange elution 
fractions; lanes 6-10, BcsCTPR 9-21 anion exchange elution fractions. 
Table 7. BcsC Protein Construct Yields 
Protein Construct Total protein yield (per litre of culture 
purified)* 
BcsCTPR 1-8 Not Determined 
BcsCTPR 1-11 ~6-7 mg/L 
BcsCTPR 1-15 ~3-4 mg/L 
BcsCTPR 4-21 ~2.5-3 mg/L 
BcsCTPR 9-21 ~2.5-3 mg/L 
BcsCTPR 12-21 ~6-7 mg/L 
*Protein yield after secondary (anion) purification for each BcsC was tabulated across at 
multiple purifications. 
Table 8. Ion Exchange Indicators for BcsC Protein Constructs 
Protein Construct mAU range* Salt percentage 
beginning** 
Salt Percentage 
Ending** 
BcsCTPR 1-11 700-1400 19 31 
BcsCTPR 1-15 480-700 5 24 
BcsCTPR 4-21 150+ 8 25 
BcsCTPR 9-21 250-350 8 26 
BcsCTPR 12-21 700-1400 9 24 
BcsCTPR 1-15SeMet 300-350 5 20 
* milli-Absorbance Units (mAU) at 305 nm 
** indicative of the salt percentage at which the proteins begin to and finishes eluting as judged 
by the elution profile 
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4.3 Dynamic Light Scattering (DLS) 
Prior to crystal screening attempts, DLS was conducted with fresh protein from the ion 
exchange columns in order to assess protein stability and polydispersity. Athough, a variety of 
diluted concentrations of protein were used for analysis, it was found that the elutions coming 
directly from the ion exchange column yielded the best results for all constructs. Early DLS data 
samples (Figure 25) indicated that either the concentrations tested were too high or that the 
protein was polydisperse. For example, analysis of BcscTPR 1-15 either contained two distinct 
species (Figure 25A), multiple aggregates (Figure 25B) and/or increasing amounts of a larger 
polydispersity (Figure 25C). After protein purification was refined to include the use of protease 
inhibitors and by decreasing the amount of time from cell lysis to downstream applications lower 
polydispersity levels were observed. For example, ample DLS data from BcsCTPR 12-21 (Figure 
26; Panel A) and BcsCTPR 1-15 (Figure 26; Panel B) indicate monodisperse samples of one species. 
This data represents 15 image acquisitions at 5 s intervals (averaged) and numerous samples 
from these two constructs that routinely achieved polydispersity levels of below 20%. These 
protein constructs were then subjected to protein crystallization attempts.  
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 A)                                                 B)                                                               C) 
 
Figure 25. Preliminary DLS Data from BcsCTPR 1-15. 
Three separate DLS profiles containing high levels of polydispersity.  A) Appears to contain two 
distinct species B) Appears to contain multiple aggregates C) Contains increasing amounts of a 
larger polydispersity. 
 
A)                                                                                B) 
 
Figure 26. DLS Dispersity Chart for (A)BcsCTPR 1-15(B) BcsCTPR 12-21. 
Dynamic Light Scattering data containing 15 acquisitions. A) BcsCTPR 1-15 protein data indicates 
an extremely low percentage of polydispersity B) BcsCTPR 12-21 protein data indicates nearly 
100% mono-dispersity. 
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4.4 Protein Crystallization 
4.4.1 Crystal Screening Trials 
Protein crystallization is usually most successful with the highest purity of protein 
accessible. In most cases that means multiple purification steps, as was the case with BcsC 
protein constructs. In addition, protein crystallization usually requires additives and precipitating 
agents to achieve nucleation points in conjunction with the correct ratio of the protein to assorted 
conditions. Thus, initial crystal trials employ surveying many crystal conditions that cover 
crystal space that has been successful in the past, along with a series of conditions that explore 
common buffers, precipitants and salts that researchers use in their purification steps.  
For each of the BcsC constructs that yielded pure protein, multiple crystal screens 
(MCSG 1-4, Top 96, Pure PEG, PACT Premier, JCSG Plus, Morpheus) in conjunction with 
multiple protein concentrations (13, 15, 20, 22, 26, 29, 30, 32, 35, 40 mg/mL) were surveyed 
(Table 9). From this research, two constructs, BcsCTPR 1-15 and BcsCTPR 12-21, resulted in high 
levels of purity (see Figure 19; lane 10 and Figure 24; lane 5, respectively) early on and, 
therefore, crystal screening of these constructs was more comprehensive than the other 
constructs (a conservative estimate of 9,000 conditions each were analyzed). The various 
conditions that elicited crystal hits from screening these two constructs are presented in Table 10 
and Table 11. BcsCTPR 1-11 was also purified to a high level through ion exchange (see Figure 18; 
lane 10) and was subjected to numerous crystal trials (approximately 3000 different conditions 
in-house) but did not yield crystal hits in any of the conditions surveyed. To accelerate and 
broaden our screening conditions, the BcsCTPR 1-11, BcsCTPR 9-21, and BcsCTPR 12-21 purified 
samples were also sent to HWI for their analysis in 1,536-well microassay plates. Screening with 
HWI was completed twice, where the first shipment included protein that was shipped 16 h 
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following ion exchange purification (storage and shipment of this protein was held at 4C until 
crystal trays were set up). Although there appeared to be crystal growth (Figure 27 A and B), 
later examination of the SONICC and ultraviolet light images (Figure 27 C and D respectively), 
conducted at the termination of the experiment, indicated that the crystals were salt in 
composition (ie. protein crystals should fluoresce under UV light due to the presence of 
tryptophan residues in each protein construct (see Table 1)). HWI screening with the same 
protein constructs (BcsCTPR 1-11, BcsCTPR 9-21, and BcsCTPR 12-21) was repeated a second time, but 
this trial differed in that samples were frozen at -80°C directly following purification and shipped 
to the facility on dry ice. Unfortunately, despite the altered preparation, only salt crystals were 
once again observed following careful examination of the brightfield microscopy, TPE-UVF, 
and SONICC images. 
Table 9. Protein Concentrations Screened for Each Construct 
Protein 
Construct 
Concentrations 
Screened 
(mg/mL) 
Crystal Screens Used Total Number of 
Conditions 
Screened 
BcsCTPR 1-8 None None 0 
BcsCTPR 1-11 20, 26, 35, 40 MCSG 1, 2, 3, 4, Morpheus, Pact Premier 
(BN-156-1-36), JCSG-Plus 
~3000 + 1536 
(HWI) 
= ~4500 
BcsCTPR 1-15 13, 15, 20, 24, 
26, 29, 32, 35 
Top 96, MCSG 1, 2, 3, 4, Morpheus, Pact 
Premier (BN-156-1-36), JCSG-Plus, Pure 
PEG 
~ 9000 
BcsCTPR 4-21 None None 0 
BcsCTPR 9-21 None None 1536 (HWI) 
BcsCTPR 12-21 15, 20, 24, 26, 
29, 30, 32, 35 
Top 96, MCSG 1, 2, 3, 4, Morpheus, Pact 
Premier (BN-156-1-36), JCSG-Plus, Pure 
PEG 
~ 9000 + 1536 
(HWI) 
= ~10500 
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Table 10. Summary of BcsCTPR 1-15 Crystal Hits 
Crystal Screen** Condition Concentration and 
Appearance 
MCSG-3 G12 (#84) 0.1 M sodium acetate pH 4.6, 
2 M sodium formate 
Numerous concentrations 
Spherulites 
Morpheus G3 (#23)  10% (w/v) PEG 4000, 20% 
glycerol, 0.2 M mixture of 
carboxylic acids, 0.1 M 
MES/Imidazole 
35 mg/mL 
Microcrystals 
MCSG-2 C8 (#59) 0.1 Bis-Tris Propane: NaOH 
pH 7.0, 1.8 M MgSulfate 
35 mg/mL* 
Micro-rod 
MCSG-2 D8 (#60) 0.2 M K Nitrate pH 6.9, 20% 
(w/v) PEG 3350 
35mg/mL* 
Micro-rod 
MCSG-1 A1 (#1) 0.1 M Hepes: NaOH pH 7.5, 
20% (w/v) PEG 8000 
13 mg/mL 
Microcrystal 
PACT Premier BN 156-1-36) 
A10 (#73) 
0.2 M MgCl hexahydrate, 0.1 
M Sodium Acetate pH 5.0, 
20% (w/v) PEG 6000 
40 mg/mL* 
Spherulites-small 
*Protein was incubated with D-glucose for a minimum of 1 hour prior to preparation 
**The numbers in brackets denote the numerical designation of the condition 
Table 11. Summary of BcsCTPR 12-21 Crystal Hits 
Crystal Screen* Condition Concentration and 
Appearance 
Top 96 A1 (#1) 0.2 M MgCl, 0.1 M Tris-HCl 
pH 8.5, 30% (w/v) PEG 4000 
20 mg/mL 
Rod-small 
JCSG-Plus D12 (#92) 0.04 M Potassium phosphate 
monobasic, 16 % w/v PEG 
8000, 20 % v/v Glycerol 
29 mg/mL 
Microcrystal 
Morpheus H1 (#85) 0.1 M Imidazole; MES pH 
6.5, 50% (v/v) precipitant 
mixture, 0.1 M amino acid 
mixture 
29 mg/mL 
Microcrystal 
MCSG-2 F6 (#66) 0.2 M sodium malonate pH 7, 
20% (w/v) PEG 3350 
30 mg/mL 
Cubic-small 
*The numbers in brackets denote the numerical designation of the condition 
       A 
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Figure 27. Representative Sample of BcsCTPR 12-21 High-Throughput Images from HWI.  
A) Sample view of 96 wells (with well #905 indicated by the red arrow) from database 
containing Hauptman-Woodward High-Throughput screening images. B) Sample microscopy 
image of crystals from well #905 (red arrow). C) SONICC image of well #905 indicates the 
presence of a crystalline object. D) UV image of 905 illustrates the absence of protein crystals. 
Microscopy, SONICC, and UV were used in combination to ensure accurate conclusions. 
 
4.4.2 Crystal Expansion Plate Trials 
 Following initial crystal screening, conditions to recreate successful crystal events in 
larger plate formats through manual setup were attempted. The first was with BcsCTPR 1-15 in the 
condition 0.1 M Hepes: NaOH pH 7.5, 20% (w/v) PEG 8000 and yielded microcrystals 
surrounded by precipitate. Unfortunately, increasing the concentration did not cause the crystals 
73 
 
to grow large enough for looping. Next the BcsCTPR 1-15 condition of 10% (w/v) PEG 4000, 20% 
glycerol (v/v), 0.2 M mixture of carboxylic acids, 0.1 M MES/Imidazole was attempted in sitting 
drop 96-well format, but crystal growth did not occur. There were no further attempts as the 
microcrystals were a lower priority than other larger crystals and the buffer contents of the 
condition were difficult to recreate without using the remaining buffer within the crystal kit. As 
IZIT dye could not confirm that the D-glucose incubated crystals were protein and they were of 
microscopic size, recreation of those conditions (denoted by a star in Table 10) was not 
attempted. The most promising condition for BcsCTPR 1-15, MCSG-3 G12 (0.1 M sodium acetate 
pH 4.6, 2 M sodium formate) had spherulite crystal morphology (poor X-ray diffraction quality 
due to thinness in one dimension over the others), so attempts were made to improve the crystals. 
First, each component in the initial condition was varied separately (0.05 to 0.2 M for sodium 
acetate and 0-3 M for sodium formate, respectively) to monitor for improved crystal growth, yet 
the variations either had no growth or the crystals looked thinner or more brittle. Expansion of 
the initial crystal condition also involved varying the stock protein concentration as well as 
crystal drop setup (reservoir buffer to protein stock ratios) and found that initial stock 
concentrations of 25 to 30 mg/mL and protein solution to reservoir buffer ratios of 3:2 and 2:1 
yielded crystals that were larger in all 3 dimensions. The pH of the condition was also varied 2-3 
units above and below the initial crystal condition (pH 5.39) but keeping the pH similar to the 
original condition yielded the best crystal results. To slow down the crystal growth in the one 
dimension relative to the other two, the incubation temperature of the crystal trays was decreased 
to 4°C instead of the normal 16°C storage temperature, but this proved to be too dramatic of a 
change, as no crystal growth was observed at this temperature. Several additives were 
supplemented into the initial condition (0.1 mM sodium acetate and 2 M sodium formate) such 
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as dithiothreitol (2 mM DTT), but no crystal formation was seen. The precipitants ethylene 
glycol and glycerol (2.5, 5, and 10% respectively) were added to the initial condition, which only 
decreased viability of the crystals due to malformation and fragility. While each of the preceding 
trials were conducted both with and without streak seeding with a variety of spherulite crystal 
stocks to introduce microcrystals as nucleation points for continued growth, only after numerous 
attempts at crystal seeding with a very dilute crystal stock (1/10 to 1/100 dilutions with crystal 
condition) were rod-like crystals isolated. Example images of the multiple isoforms obtained 
from these crystal seeding results are displayed in Figure 28, including the refined spherulites 
(Figure 28A) and the rod-like crystal (Figure 28B). Single crystals isolated from these drops 
were assessed to have resolutions of ~3.5Å (Figure 29) following X-ray diffraction analysis at 
the Canadian Light Source (CLS). However, the cryoprotectant (16.5% (v/v) glycerol, 1.32 M 
sodium formate, 66 mM sodium acetate) used to stabilize these crystals was not ideal and the 
diffraction pattern was smudged leading to unusable reflections in the diffraction images. 
Replicating the growth conditions for this crystal in additional trials with a focus on seed quality 
(ie. using the best-looking crystals for successive seeding) and improved cryoprotectants for 
diffraction (consisting of 3.96 M sodium formate and 66 mM sodium acetate) successfully led to 
a 3.1Å resolution dataset (data statistics are summarized in Table 12 and an image of the 
diffraction pattern is depicted in Figure 29). Solvent content analysis was consistent with one 
copy in the unit cell (2.34 Matthews Coefficient).  
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 Table 12. Statistics for X-ray Data Collection and Processing of BcsCTPR 1-15 
  
Diffraction Source CMCF beamline 08B1-1  
Wavelength 0.9795 
Temperature 
100 K 
Exposure time 
0.2s 
Number of images collected 
180 
Oscillation range 
0.2 degrees per image 
Space group C2 
Cell dimensions   
   a, b, c, (Å) 148.54, 52.62, 91.25 
   α, β, ɣ, (°) 90, 117.28, 90 
Resolution range (Å) 48.88-3.10 (3.21-3.10) 
Total number of reflections 
38478 (3791) 
Total number of unique reflections 
11574 (1115) 
Rmeas 0.052 (0.585) 
I/σI 14.0 (2.60) 
Rpim 0.028 (0.313) 
CC1/2 0.999 (0.873) 
Completeness (%) 99.6 (99.9) 
Redundancy 3.3 (3.4) 
Mosaicity 0.26 
 
Attempts to recreate crystal hits with BcsCTPR 12-21 were successful for the Top 96 A1 (0.2 
M MgCl, 0.1 M Tris-HCl pH 8.5, 30% (w/v) PEG 4000) and MCSG-2 F6 (0.2 M sodium 
malonate pH 7, 20% (w/v) PEG 3350) conditions. Initially, several expansion plates were 
conducted with the Top 96 condition using different concentrations of buffer (0.1 to 0.3M), and 
PEG (10 to 30%), which included different ratios of stock protein solution to reservoir buffer in 
each plate created (similar to that outlined in the last paragraph). The crystals yielded from an 
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optimized drop (2:1 protein to buffer ratio; Figure 30) were large and promising, yet after 
diffraction, the resolution was found to be quite poor (12-14 Å).  Attempts were made to improve 
this resolution by harvesting newly formed crystals that were unblemished, yet no improvement 
was seen in the resolution, which remained between 12-14 Å. Although the exterior appearance 
of the crystals looked refined, the interior stacking was so poor that it seemed impossible to 
optimize. Crystals from the MCSG-2 F6 condition were more recently recreated (Figure 31) and 
X-ray diffraction analysis needs to be performed on this condition to further justify crystal 
optimization.  
 A)                                                               B) 
  
Figure 28. Representive Images of Different Isoforms of BcsCTPR 1-15. A) Multiple crystals 
extending into drop with end available for harvesting with a growth time of approximately 6 
months. B) Long rod-like crystal before harvesting with a growth time of approximately 4 
months. Each crystal condition contained 0.1 M sodium acetate pH 4.6, 2 M sodium formate. 
100 µM  
100 µM  
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Figure 29. Image of BcsCTPR 1-15 Crystal Resolution ~3.5Å. Crystal condition contained 0.1 M 
sodium acetate pH 4.6, 2 M sodium formate. Panel A depicts an image of the crystal growing in 
the drop prior to harvesting for analysis after a growth time of approximately 4-5 months. Panel 
B depicts a representative diffraction image.  
  
Figure 30. Representative Crystal Image of BcsCTPR 12-21. Crystal condition containing 0.2 M 
MgCl, 0.1 M Tris-HCl pH 8.5, 30% (w/v) PEG 4000 Image of BcsCTPR 12-21 crystal resolution 
~14Å with a growth time of approximately 6 weeks.  
 
 
100 µM  
100 µM  
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Figure 31. Crystal Image of BcsCTPR 12-21. Crystal measured at approximately 100 µL and 
condition containing 0.2 M sodium malonate pH 7, 20% (w/v) PEG 3350 with a growth time of 
approximately 3 months. 
 
4.5 Molecular Replacement 
 Molecular replacement was attempted with the BcsCTPR 1-15 data using a combination of 
programs across the Phenix and CCP4 online databases. The automated molecular replacement 
features of these programs (MRage in Phenix and BALBES, MrBump and MoRDa in CCP4 
online) performed processes that scan the existing PDB databases for hits based on sequence 
identity and then perform molecular replacement with the experimental data. Despite multiple 
trials, the best output with this platform was through the BALBES server (https://ccp4serv7.rc-
harwell.ac.uk/ccp4online/) with an Rwork/Rfree of 0.5440/0.5470 and a probability of solution of 
42.29%. However, attempts to Autobuild with this model were not successful. With the Phenix 
suite of programs MRage and Phaser were also used in combination with different PDB files 
from the top five BLASTP and Phyre2 results (Tables 4 and 5, respectively) along with the PDB 
files from BcsCTPR 1-6 (PDB:5xw7) and AlgK (PDB:3e4b). Trimming of each of these models to 
an alanine backbone was also conducted and attempted as an alternate route to fit the data. The 
best results so far have consisted of trimming the BcsCTPR 1-6 model to an alanine backbone with 
100 µM  
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2 copies in the asymmetric unit. The output statistics have indicated that this solution has a log 
likelihood gain (LLG) of 48.24 and a translation function z score (TFZ) of 4.5. Rounds of 
Autobuilding in Phenix using Resolve were attempted with this and other models and the most 
successful outputs have led to structural models with an Rwork/Rfree of 0.3920/0.5827 that are not 
good candidates to pursue given the poor fit of the model to the density (as evidence in Figure 
32).   
 
Figure 32. Representative Images of the Molecular Replacement and Autobuild Output of 
BcsCTPR 1-15. Images were rendered in Coot where the blue mesh represents the electron density 
(rendered at 2 sigma) to which the structural model (yellow backbone) has been fit. Panels A-D 
depict four separate regions of the single chain modeled into the asymmetric unit.   
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4.6 Selenomethionine Expression, Purification, and Crystallization  
The introduction of selenium into a protein via supplementation of selenomethionine is a 
common method when attempting to solve the phase problem using heavy atoms in 
crystallography (141). Figure 33 illustrates the SDS-PAGE image from the expression, IMAC 
purification and anion exchange chromatography of BcsCTPR 1-15 with SeMet minimal media. The 
yield of protein was less (~2.5 mg/L of culture) when compared with expression in rich media 
(~3-4 mg/L of culture), but enough protein was purified to proceed to crystal trials. Initially, a 
test expression of 1 L of SeMet culture was conducted, purified, and placed into crystals trays 
with seeding using the same condition (0.1 M sodium acetate pH 4.6, 2 M sodium formate) 
diffracted in the native BcsCTPR 1-15 and protein crystals successfully formed. Thereafter, a larger 
4 L culture expression was performed, and the resultant yield of protein was approximately 2.5 
mg/L of pure recombinant protein following IMAC and ion exchange purification (Figure 33, 
lane 9 and 10; Figure 34, peak at 120 mL). This protein sample was used to set-up multiple 
replicates of the successful crystal condition for this construct and the early (2 wks old) 
representative images of the SeMet crystals (Figure 35) indicate a possibility of diffraction 
quality crystals given enough time.  
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Figure 33. SDS-PAGE Expression and Purification of SeMet BcsCTPR 1-15. SDS-PAGE 
analysis (12% (v/v)) of BcsCTPR 1-15 SeMet minimal media expression of 1 L cultures incubated 
at 22°C and 160 rpm shaking, Ni-NTA purification fractions, and an anion exchange elution. 
Lane 1, molecular-weight markers (kDa); lane 2, expression induction time 0 sample (20 mL of 
sample); lane 3, expression time 4 h sample (15 mL of sample); lane 4 expression time 16 h (10 
mL of sample); lane 5, Ni-NTA column unbound lysate; lane 6, wash with lysis buffer (no 
imidazole); lane 7, wash 1 (20 mM imidazole); lane 8, wash 2 (40 mM imidazole); lane 9, 
elution buffer (250 mM imidazole); lane 10, fraction from anion exchange chromatography 
column. 
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Figure 34. Anion Exchange Purification Profile of SeMet Rich BcsCTPR 1-15. The blue line 
represents mAU for the protein BcsCTPR 1-15, where the peak is 355 mAU. The green line 
represents the percentage of salt eluting. This SeMet containing protein does not produce a 
typical BcsC chromatograph. The first peak represents the protein passing over the anion column 
which does not seem to bind to the column until supersaturated. 
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A)                                                    B)                                                   C) 
 
Figure 35. Representive Images of Different Isoforms of SeMet BcsCTPR 1-15. Crystal 
condition containing 0.1 M sodium acetate pH 4.6, 2 M sodium formate with a growth time of 
approximately 4 weeks. 
 
4.7 Small Angle X-ray Scattering (SAXS) 
 SAXS analysis was conducted using Frameslice to merge the data, followed by 
SCATTER to analyze and fit the data patterns. Afterwards, the program PRIMUS was used to fit 
the P(r) function for later processing with online servers (ATSAS and SIBYLS). The initial 
results of manual data fitting using SCATTER and later automated online processing using 
ATSAS is presented in Table 13. The Rg value is the radius of gyration of a particle and can be 
obtained from Guinier fitting both manually or using an auto Rg function (128). The Rc value of 
a particle is the cross-sectional radius and when used in conjunction with the Rg value it can 
yield information about the shape of a particle. For example, an elongated particle such as BcsC 
would be expected to have an Rg value twice as big as the Rc value because the protein particle 
is expected to be longer than wider. A globular particle would be expected to have similar Rg and 
Rc values. These trends of an elongated protein agree with the values collected across all BcsC 
100 µM  100 µM  100 µM  
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constructs, which all have at least double the Rg value compared to Rc. The Dmax (Å) is the 
maximum diameter of the particle and in the case of BcsC, the maximum diameter was similar in 
all four constructs. However, one should exercise caution when interpreting the data as ab initio 
shape reconstruction requires monodisperse data (142), but the chi-squared values of the raw data 
for BcsCTPR 9-21 and BcsCTPR 12-21 constructs (1.36 and 0.46, respectively) support that there is 
decent data for fitting and interpretation. Furthermore, when solving the inverse Fourier 
transform of the scattering profile, the Dmax is an adjustable parameter and can be highly 
sensitive to sample quality and is difficult to predict with accuracy (142, 143). It should also be 
noted that in cases where a scattering particle has flexibility it may be difficult to choose a Dmax 
value, which may apply to BcsC, a protein that has been reported to have a flexible hinge region 
(90). The lowest Dmax value (117 Å) was from BcsC
TPR 9-21 and the model of this construct (as 
illustrated in Figure 36) adopts a bend or U-shaped fold and has a smaller value to that of the 
shorter BcsCTPR 12-21 construct, which has a fully elongated model (depicted in Figure 37) and the 
highest Dmax value (128 Å). It may be that the discrepancy between these values is an indication 
of greater flexibility within the longer BcsCTPR 9-21 construct.  
 The BcsCTPR 1-11 and BcsCTPR 1-15 SAXS models that encompass the region of the known 
BcsCTPR 1-6 crystal structure (PDB:5xw7) were manipulated in PyMOL to overlay the structures 
using DAMAVER. BcsCTPR 1-6, in each of the two overlaid models (Figure 38 and 39, 
respectively) fit the TPR 1-6 regions in a lobe at the bottom of the SAXS model in an orientation 
where the C-terminus of BcsCTPR 1-6 faces towards the unoccupied space of the SAXS model and 
the N-terminus of the elongated structure is at the other end of the lobe. We deemed this as an 
important quality control check for the fitting, as the unaccounted-for space in the SAXS model 
was due to the missing TPR regions (ie. TPRs 7 and above) in the model that would be C-
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terminal to TPR 6.  As expected, BcsCTPR 1-15 does appear slightly larger overall in size, but 
interestingly has a tighter fit of the N-terminus to the BcsCTPR 1-6 model.  However, these models 
are predictive in nature and further studies involving other structural techniques would need to be 
done to correlate these differences in N-terminal flexibility of conformations. 
Table 13. SAXS Analysis Values from SCATTER and ATSAS 
 Scatter Values ATSAS Values 
Construct Rg Value Rc Value Rg Value Dmax (Å) 
BcsCTPR 1-11 37.6 17.6 38.51 125.5 
BcsCTPR 1-15 49.1 22.1 37.87 122.5 
BcsCTPR 9-21 46.9 19.8 36.5 117 
BcsCTPR 12-21 38.1 17.3 37.86 128 
 
A)                                                                              B) 
  
Figure 36. GASBOR Rendering of BcsCTPR 9-21. Ab initio spherical representation of BcsCTPR 
9-21 constructed of dummy residue models displaying a view of each axis (A and B). All models 
processed on the ATSAS server.  
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A)                                                                                B) 
  
Figure 37. GASBOR Rendering of BcsCTPR 12-21. Ab initio spherical representation of BcsCTPR 
12-21 constructed of dummy residue models displaying a view of each axis (A and B). All models 
processed on the ATSAS server. 
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A)                                                                                B) 
 
Figure 38. Structural Fitting of BcsCTPR 1-11 SAXS Model with BcsCTPR 1-6 PDB Model. 
PyMOL rendered fitting of DAMAVER rendered SAXS model of BcsCTPR 1-11 with poly-alanine 
structure of BcsCTPR 1-6.  
A)                                                                                B) 
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Figure 39. Structural Fitting of BcsCTPR 1-15 SAXS Model with BcsCTPR 1-6 PDB Model. 
PyMOL rendered fitting of DAMAVER rendered SAXS model of BcsCTPR 1-15 with poly-alanine 
structure of BcsCTPR 1-6. 
5. Discussion 
5.1 Bioinformatics 
 Bioinformatics provided a useful framework for the planning of downstream 
experimentation with programs like ProtParam, but also was pivotal for analyses with SAXS, 
molecular replacement and SeMet-derivative generation. For example, the number and position 
of methionine residues is pertinent information for SeMet incorporation into each construct as 
there must be enough to make structure solution by this route plausible. The phasing power of a 
heavy atom derivative is dependent upon the resolution of the crystal structure and the size of the 
protein, as a higher resolution and a smaller protein increases the probability of success (141), 
but a general rule of thumb is to have one SeMet incorporated for every 75-100 amino acids 
(144), which BcsC narrowly satisfies. One notable characteristic of BcsC highlighted through the 
program ProtParam was the absence of cysteine residues, which means BcsC is unable to form a 
disulphide bond between protein chains (145). Disulphide bonds can be important to the natural 
stability of the protein (i.e. folding) or in the case of oxidative-reductive cycling, the disulfide 
bond may be important for a proteins activity (145). The Dsb proteins facilitate the correct 
formation of disulphide bonds for proteins in the periplasm should this be necessary (145). 
However, the lack of cysteine residues (and disulphide bonds) may suggest that BcsC is meant to 
be flexible in nature. The formation of cysteine bonds could limit its ability to facilitate 
interactions with other proteins in the periplasm or even cellulose chains.  
A subsequent program that was used frequently in bioinformatics searches, Phyre2, was 
also used to create hypothetical structural models of the entire TPR domain, as well as all 6 BcsC 
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constructs. Figures 9-15 were all based on proteins with some homology at the amino acid level 
to BcsC. All the structural models identified had TPR helices and/or contained a high number of 
helices with suggested involvement in protein-protein interactions (146–150). For example, the 
structure of O-linked N-acetylglucosamine transferase contained 11.5 TPR repeats that formed 
an elongated superhelix suggested to be a molecular scaffold for other proteins, which in a larger 
complex facilitates glycosylation of other proteins (148). This functional homology coincides 
with the assumed BcsC TPR domain interactions with other periplasmic proteins, such as BcsZ 
and BcsA-BcsB, and also with the closely related alginate system in which the TPR protein 
AlgK is suggested to have interactions with the other periplasmic proteins AlgX, Alg44, and 
AlgE (74, 151, 152). Although these modelling results are interesting, the proteins that had 
higher amino acid identity returned through BLAST searches (Table 4) were also deemed 
relevant, as Phyre2 can sometimes miss newly deposited structures in the PDB database. Given 
that amino acid identity is a good indicator for the success of molecular replacement models, 
combining the PSI-BLAST iteration with Phyre2 was a good strategy, which was designed to 
increase the probability of obtaining a successful molecular replacement for structure solution. 
All BcsC constructs also contained a percent identity of between 22 and 25% with the amino 
acid sequence of AlgK, and between 71 and 73% with BcsCTPR 1-6 (as assessed through Clustal 
Omega alignments in our bioinformatics analysis pipeline), so they were included as molecular 
replacement modelling options as well.  
 Disorder prediction software was used to search for disordered regions amongst BcsC 
protein constructs, as proteins that contain disordered regions can be difficult to purify and 
crystalize (153–155). Unstructured or disordered regions can direct functions within a protein 
(156) but can interfere with ordered packing for crystallization. Therefore, disorder prediction 
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can prove pivotal when creating protein constructs to ensure proper study of both ordered and 
disordered regions (157). Because each disorder prediction algorithm has its weaknesses (109), a 
meta approach was taken to study disordered regions. Both metaPrDos and DisMeta contain 
several different programs (158, 159) and the combined results for all BcsC constructs indicated 
that there may be considerable disorder at each terminus, which could be explained in part by the 
His6-tag. However, as two of the six protein constructs were crystalized, it appears the disorder at 
the termini had a minimal effect, if any, on protein folding. In addition, BcsCTPR 4-21 contains a 
short series of disordered amino acids predicted slightly above the 5% false positive confidence 
scale in the middle of the protein. While this region may be insignificant for a protein as large as 
BcsCTPR 4-21 (74.1 kDa), since soluble protein was consistently produced, it has yet to be 
determined if it played a role in crystal packing as the structure of this construct remains 
unsolved. 
5.2 Protein Expression and Purification 
5.2.1 Protein Expression 
The first objective of this thesis was to express and purify each of the protein constructs 
in our panel of BcsC derivatives. A major part of this objective was spent on optimizing the 
expression conditions for each of the BcsC protein constructs by surveying IPTG concentrations, 
growth temperatures and the length of expression. A general consensus across the protein 
constructs BcsCTPR 1-8, BcsCTPR 1-11, BcsCTPR 1-15, BcsCTPR 4-21, BcsCTPR 9-21, and BcsCTPR 12-21 
indicated that optimal conditions involved inoculation at 37°C, induction with 1 mM IPTG and 
incubation at 22°C for 16 h while shaking at 200 rpm throughout the culture period. During 
preliminary research expression was conducted at 37°C, yet it was later determined that lowering 
the temperature increased the yield of soluble protein. This was consistent with published 
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literature that found lowering the temperature and IPTG concentration may slow the translation 
machinery and give expressed protein more time to fold properly; thereby, increasing soluble 
protein yields (160). While some constructs fared slightly better with moderate changes, the 
general expression protocol was important for ease of use when multiple constructs were being 
expressed and purified simultaneously or in close succession (which was frequently). Thus, with 
respect to the first thesis objective, all protein constructs were successfully expressed. 
5.2.2 Protein Purification 
Following expression, a second part of objective 1 was to subject each of the protein 
constructs to a platform of purification steps to yield sufficient quantities of soluble protein for 
objectives 2 and 3. The first protein purification step conducted for all recombinant protein 
constructs was IMAC with Ni-NTA resin beads as each vector was engineered with a His6-tag to 
facilitate this type of purification. All affinity tags have the potential to interfere with biological 
activity or crystallization of a protein, the advantages of a His6-tag are that it is small, relatively 
cheap, can be regenerated many times, contains a large binding capacity, operates well under 
denaturing conditions, and can interact with multiple chromatographic matrices (161). This may 
have contributed to the successful completion of protein purification through the IMAC stage for 
all constructs using a general protocol that involved using increasing amounts of imidazole to 
wash the contaminants and finally elute the target recombinant protein. For all constructs a 
further purification step was needed, as SDS-PAGE analysis of BcsC indicated numerous protein 
contamination bands at multiple weights across all constructs. For secondary purification, ion 
exchange chromatography was conducted and yielded a purity of over ~95% (as judged by SDS-
PAGE analysis of the fraction).  
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While this research was able to successfully express and purify each of the 6 BcsC 
derivatives, the constructs did not purify to the same degree and amount. BcsCTPR 1-11 and 
BcsCTPR 12-21 consistently yielded the largest amounts of purified protein (~6-7 mg/L culture; 
Table 7) with our standard two-step purification process (eg. IMAC followed by ion exchange). 
BcsCTPR 4-21 (~2.5-3 mg/L culture), BcsCTPR 9-21 (~2.5-3 mg/L culture), and BcsCTPR 1-15 (~3-4 
mg/L culture) all had lower average yields, but still ample amounts for downstream analyses. Of 
these five constructs, there may be many reasons for different yields between them. One 
possibility is the construct size, since the two greatest yields came from constructs BcsCTPR 1-11 
and BcsCTPR 12-21 that expressed proteins of the lowest molecular mass (~47.3 kDa and ~40 kDa 
respectively); whereas the lowest yields came from BcsCTPR 4-2*1 (~74.1 kDa), BcsCTPR 9-21 (~52.4 
kDa), and BcsCTPR 1-15 (~64 kDa). Other researchers have noted that the chances of successfully 
expressing soluble proteins at molecular weights over ~60 kDa decreases significantly due to the 
propensity to precipitate into inclusion bodies and/or misfold (140). However, in our case, by 
combining several expression pellets, the amount of protein harvested was sufficient for all 
downstream applications. Contrary to the size argument, BcsCTPR 1-8 was successfully expressed 
and purified, but was not pursued further since multiple rounds of optimization did not lead to 
protein with a high degree of purity and stability. However, the complement of five constructs 
that were used further encompassed the 1-8 TPR region, so we felt that this region would be 
adequately covered in the repertoire of the 5 constructs we were successful with. 
5.3 Dynamic Light Scattering 
DLS was successfully utilized to monitor the protein polydispersity in efforts to improve 
the suitability of buffers for downstream applications, mainly crystallization. Early results for 
protein constructs BcsCTPR 1-15 and BcsCTPR 12-21 yielded very aggregated and polydisperse 
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samples (Figure 25) that also did not crystalize well. However, the polydispersity character of 
these samples was overcome by varying several important factors. For example, results indicated 
that polydispersity levels were significantly affected by increasing the purity of the protein 
sample, conducting DLS experiments in a time sensitive manner, and varying the sample 
concentration of the protein used in the DLS experiments. The most successful DLS trials were 
conducted with protein newly purified from an anion exchange experiment that was filtered and 
adjusted to an approximate concentration of 1-2 mg/mL (Figure 26A & 26B). Following the 
adoption of some these conditions, there was a direct improvement in the crystallization 
propensity of the BcsCTPR 1-15 and BcsCTPR 12-21 protein constructs. 
5.4 Protein Crystallization 
As part of the second objective of the present research, the stability and composition of 
each of the purified proteins was optimized for crystallization trials. This step was necessary as 
protein crystallization is most successful at high levels of purity and conducted under as many 
different conditions as possible (154), even though this does not guarantee protein crystals will 
form. To maximize the chances of success, the addition and optimization of the salt 
concentration is important since salts can aid macromolecules in associating with one another, 
through competition with proteins for water molecules to fulfill their electrostatics requirements 
(154). Across several of the recorded crystal hits for BcsCs conditions (Table 10 & 11) sodium 
can be found. This may be due to a combination of favourable protein-ion interactions or the 
dehydration effect previously mentioned. From the literature, BcsCTPR 1-6 was crystallized to a 
resolution of 3.27 Å in a condition that contained 100 mM MES (pH 6.2), 3.5 M sodium chloride 
(90). When combining these results, it seems clear that BcsC constructs behave favourably when 
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interacting with sodium and future attempts at crystallization should examine sodium-containing 
conditions more closely. 
 BcsC was successfully crystallized in two TPR overlapping constructs (BcsCTPR 1-15 and 
BcsCTPR 12-21) in several conditions. Although one of the concentrations was only 13 mg/mL, the 
majority of BcsC crystals hits came at concentrations of 29 mg/ml and above, which was 
consistent with the aforementioned BcsCTPR 1-6 that diffracted at 60 mg/mL (3.27 Å). Of the four 
crystal hits for BcsCTPR 12-21, only the two most promising conditions were reproduced. Multiple 
trials were conducted to reproduce and optimize a rod-like crystal from the first condition (0.2 M 
MgCl, 0.1 M Tris-HCl pH 8.5, 30% (w/v) PEG 4000) using grid style screening with variations 
of buffer, PEG, salt and protein concentrations. While over a dozen promising crystals (large and 
good three-dimensional character) were harvested and sent for diffraction, the diffraction quality 
from this crystal form was consistently poor and ranged between 12-14 Å (Figure 30). Multiple 
attempts were made to harvest fresher crystals for diffraction, but the results were unchanged, 
and the condition was abandoned in favour of other constructs.  
The second promising crystal condition (0.2 M sodium malonate pH 7, 20% (w/v) PEG 
3350 (MCSG-2 F6) with BcsCTPR 12-21 took far longer to replicate. This crystal required months 
to grow and only recently has a small cubic crystal (Figure 31) been identified in the condition. 
This crystal does appear promising but future experimentation to assess the diffraction quality of 
the crystal (and potential further optimization) still needs to be performed, which is beyond the 
scope of this research due to time constraints.  
Our moderate success with BcsCTPR 12-21 crystallization has proved time consuming and 
encountered multiple hurdles, but this is not unique for the crystallization of TPR containing 
proteins. Researchers of the homologous TPR containing protein AlgK were met with difficulties 
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crystallizing and switched to a different organism for crystallization (74). Also, the group 
involved in crystallizing BcsCTPR 1-6 also attempted to solve the structure of BcsCTPR 1-17 but were 
unable to attain a high enough diffraction quality ( 7–8 Å) (90). From these results it is clear that 
the characterization of TPR export proteins is extremely difficult, which may be due to the 
flexible nature of TPRs in general (87, 90) and that continued optimization of BcsCTPR 12-21 and 
other constructs is still worthwhile.  
For BcsCTPR 1-15, three crystal conditions were identified in initial trials (96-well, hanging 
drop, Gryphon-setup plates) as having microcrystals worth pursuing. However, for two of the 
crystal conditions (10% (w/v) PEG 4000, 20% (v/v) glycerol, 0.2 M mixture of carboxylic acids 
and 0.1 M MES/Imidazole and 0.1 M Hepes: NaOH pH 7.5, 20% (w/v) PEG 8000), manual 
setup in larger chambered plates (24-well plates) utilizing sitting drop kinetics under the same 
conditions did not lead to usable crystal forms. Instead, the crystals were often far smaller and 
nucleated growth in a spherulite type of pattern, rather than individual microcrystals. This 
variance may be due to the difference in sitting versus hanging drop and increased drop volume 
(nl to l, respectively) that affected vapor diffusion. In the presence of a glucose additive (to 
mimic cellulose ligands for the protein), three successful replicates did lead to two micro-rod and 
small spherulite crystals (Table 10), but upon testing with IZIT dye for protein composition it 
was still unclear following addition of the dye, due to the small size of these crystal forms.  The 
third BcsCTPR 1-15 condition (0.1 M sodium acetate pH 4.6, 2 M sodium formate) behaved 
similarly to the other conditions at the start with one spherulite crystal in the initial trials. 
Improvement of the quality of the crystals was not achieved through altering protein 
concentrations, pH, temperature and additives, but instead through iterations of microseeding of 
new crystal conditions by the streak seeding method that led to thicker growth of rod-like 
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crystals (see different isoforms Figure 28) with diffraction quality to 4 Å. Successive seeding 
attempts over a 4 month period led to even better growth with much larger and thicker rod-
shaped crystals with 3.5 Å resolution diffraction (Figure 29). Trials to improve the 
cryoprotectants with these crystals (glycerol and ethylene glycol switched for high 
concentrations of sodium formate) led to improved diffraction images (low anisotropy of 
reflections) and an enhanced resolution of approximately 3 Å. These results may be due to the 
increase in sodium formate acting as a dehydrant, as well as a cryoprotectant, similar to what has 
been identified in other studies (154). 
5.5 Molecular Replacement 
Molecular replacement was conducted using multiple programs through the Phenix and 
CCP4 online databases as automated pipelines and with targeted PDB files from Phyre2 and 
BLAST searches (Tables 2 and 3 respectively) with favourable homology to BcsC. In addition, 
the PDB files from BcsCTPR 1-6 and AlgK were also used in various forms and combinations with 
each other as well as the other PDBs. The best solution obtained was with an alanine trimmed 
variant of the BcsCTPR 1-6 structure that had LLG and TFZ molecular replacement statistics of 
48.24 and 4.5, respectively. Despite these lower statistical ratings, rounds of Autobuilding in 
Phenix were attempted with this and other models and the most successful outputs have led to 
structural models with an Rwork/Rfree of 0.3920/0.5827, which is indicative of possible over-
refinement of the model given the divergence of the two parameters. Ideally, both the Rwork and 
Rfree should decrease in value together since the Rfree represents the validation set of data that has 
not been manipulated and is an indication of whether the model fits the original dataset with any 
statistical confidence. While future work with molecular replacement will continue, as new 
models and structures are solved or made available constantly, the complimentary alternative to 
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this method, SeMet-derivative crystals, was also attempted. Future work could also consist of 
heavy metal soaking into the crystals to use these atoms as a phasing method to solve the 
structure of BcsC. 
Even in the absence of a resolved structure, the diffraction data for BcsCTPR 1-15 have 
supported previously reported data. For example, the unit cell values of the crystal data that has 
been collected suggest an extended structure in one dimension (148 Å) that is similar to other 
TPRs. The previously reported crystal structure and SAXS data of BcsCTPR 1-17 also found that 
this construct covered 120 Å in length (90). These researchers further suggested (90) that this 
may be enough to span the periplasm, which is proposed to be 150-180 Å (163) in length. Thus, 
future work with our crystal constructs will shed more light on this theory. 
5.6 Selenomethionine Crystallization 
 SeMet incorporation into a protein is a common method for solving the phase problem in 
crystallography (141) and was conducted in this study. Expression yields with the SeMet 
derivative of BcsCTPR 1-15 led to slightly lower than native yields, which was likely due to the 
reduced nutrient load in the minimal media, but still resulted in enough protein for crystal trials 
that had a higher level of purity (see Figure 19 and 32 for native and SeMet derivatives, 
respectively). SeMet derived protein was successfully crystallized using seeding with BcsCTPR 1-
15 in the exact same condition as the native BcsCTPR 1-15 (0.1 M sodium acetate pH 4.6, 2 M 
sodium formate with a final buffer pH of 5.4). Comparison of the crystal images of the native 
(Figure 29) and the SeMet protein derivative (Figure 35) crystals clearly show that the native 
crystals are thicker. However, this difference likely has to do with time since the native crystals 
have grown for twice as long (2 months as opposed to 1 month for the SeMet derivative). The 
published structure of BcsCTPR 1-6 followed this seemingly same trend as the SeMet variant  
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diffracted to only 3.4 Å, while the native protein was 3.27 Å (90). In a separate study, the 
homologous export protein AlgK was solved using SeMet phasing (2.8 Å), where the native 
form was also crystallized to a higher resolution (2.5 Å). The success of both groups of 
researchers is promising, although more time may be required to develop SeMet variant crystals, 
so monitoring of the plates is ongoing and will be followed by testing the X-ray diffraction 
quality of the crystals once they are larger.  
5.7 Small Angle X-ray Scattering (SAXS) 
 SAXS is a technique that can apply to a wide range of particle shapes and sizes that has 
quickly become a major tool for characterizing macromolecular systems (128) and was used 
during the present study. The amount of diffraction data generated by a SAXS analysis is 
cumbersome to manipulate with the mathematical tools and algorithms available but can produce 
data that provides some valuable model interpretative results. When used in conjunction with 
other techniques, such as X-ray crystallography, the results of SAXS can be even more powerful 
by correlating evidence between two structural models. The current project was not able to 
provide a structure to balance the results from SAXS, so a structure of BcsCTPR 1-6 from the PDB 
was used instead. Initial SAXS data (Table 13) was successful in generating models for the 4 
tested BcsC constructs as elongated particles (as opposed to globular), which was consistent with 
what is known of the composition of BcsC. When the P(r) function was plotted, a long protein 
consisting of dummy residues was constructed for all 4 constructs, of which only the two C-
terminal constructs were presented (BcsCTPR 9-21; Figures 36 and BcsCTPR 12-21; Figure 37), as the 
two N-terminal constructs (BcsCTPR 1-11; Figures 38 and BcsCTPR 1-15; Figure 39) were displayed 
with the PDB of BcsCTPR 1-6 in a fitted model instead. When visually comparing the two models 
it is clear that BcsCTPR 1-15 is slightly bigger than BcsCTPR 1-11 and seems to have a closer fit. In a 
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recent study, SAXS data from BcsCTPR 1-17 was presented and suggests that BcsCTPR 1-17  is 120 Å 
in length (90). Since the bacterial cell envelope is believed to span 150-180 Å (163), this allowed 
for the theory that full length of the TPR region of BcsC may span the entire periplasm; thereby, 
connecting BcsB to the ß-barrel domain of BcsC to facilitate the export of cellulose (162). Our 
current research also supports this theory given that the conservative estimates of Dmax values 
(approximately 120 Å) and the unit cell values from the diffraction data collected (BcsCTPR 1-15 = 
148 Å) suggest there is enough length in these models to cover even more of the periplasmic 
space than previously suggested in the literature (163). 
5.8 Summary and Significance 
 Bacteria can adapt using many strategies for survival across a range of environments and 
one of the most prevalent strategies in bacterial infections is to utilize biofilms, thereby, making 
research on exopolysaccharide secretion systems vital for the prevention of and controlling the 
spread of biofilms. Without the presence of exopolysaccharides in a biofilm, the antibiotic 
resistance decreases dramatically (68, 164, 165). Although the study of bacterial cellulose 
secretion systems has been important in industrial fields, such as cosmetics, drug delivery, and 
food processing (166), it is also crucial in the medical field, due to its role in pathogenesis with 
respect to Escherichia.coli (22), Salmonella spp. (4), and Pseudomonas aeruginosa (23). The 
present research was conducted to help bridge the understanding between current 
exopolysaccharide secretion systems present in enteric bacteria and areas of the cellulose 
biosynthetic system that are less defined. Specifically, this research focused on elucidation of 
key details about the bacterial biosynthesis protein BcsC. 
 BcsC is predicted to be responsible for export of cellulose from the cytoplasm to the 
extracellular space and presents a significant target for inhibition of cellulose production by the 
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cell; which, in turn, could aid in prevention and control of biofilms (47). BcsC has functional 
(162), structural (74, 90), and sequence (22 to 25% identity) homology to AlgK, a previously 
characterized protein involved in exopolysaccharide export (74) in the characterized alginate 
system (162). However, key differences exist between them, for example, BcsC contains several 
more TPR regions, which may add enough length to span the periplasm (as evidenced by our 
Dmax SAXS data) and facilitate direct protein-protein interactions with the synthesis complex 
comprising BcsA-BcsB. This setup would be novel compared to previously characterized 
alginate and PNAG secretion systems, but the relevance and mechanism of interactions are still 
unknown. Currently, a structure of the first 6 TPR regions of BcsC exists that presented multiple 
conformations and suggests flexibility within the structure (90), yet much is left unanswered due 
to the resolution of the model, discrepancies in the overall number of predicted TPR regions, and 
the absence of a complete model that predicts specific functions with respect to the proposed 
protein-protein interactions. We hypothesized that a structural investigation of the N-terminus of 
BcsC would confirm that it contains a series of TPR folds and that this region is important to 
ligand binding. The objectives entailed first expressing and purifying all protein constructs and 
secondly, performing extensive crystal screening, followed by the refinement of promising 
conditions that may lead to improved quality for X-ray diffraction data. The final objective was 
to build a structural model of the BcsC protein constructs through a combination of X-ray 
crystallography and SAXS experiments. 
 With respect to objective 1, BcsC was successfully expressed and purified in all 
constructs, five of which reached a high level of purity (95%) after secondary purification. While 
BcsCTPR1-15, BcsCTPR 12-21, BcsCTPR 1-11, and BcsCTPR 9-21 could be readily purified with our 
general protocol, BcsCTPR 9-21, BcsCTPR 4-21, and BcsCTPR 1-8 were difficult to work with and 
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initially abandoned in preference of the others. However, late in the project, work with BcsCTPR 
9-21 and BcsCTPR 4-21 resumed successfully so future research can also focus on downstream 
analyses with these C-terminal protein constructs. Together, this panel of purified constructs 
(BcsCTPR 1-15, BcsCTPR 12-21, BcsCTPR 1-11, BcsCTPR 9-21 and BcsCTPR 4-21) are noteworthy because 
they span the entire BcsC region and improved our chances for successful crystal hits (due to 
size or disorder), as was evidenced by the BcsCTPR 4-21 and BcsCTPR 1-8 constructs. This work is 
important because it represents the successful report of regions beyond TPRs 1-6 (90) being 
expressed and purified to near homogeneity. The entire panel of BcsC constructs now provides a 
unique opportunity to crystallize sub-regions of TPRs or perform functional work that may prove 
to have specific roles in interacting with BcsA/B and newly formed cellulose (i.e. the N-terminal 
containing TPR constructs) or the outer membrane beta-barrel (i.e. the C-terminal containing 
TPR constructs) as has been inferred in the literature (162). Given that a standard protocol has 
now been generated to produce protein from 5 of the 6 constructs attempted, the only remaining 
future directions for this objective would be to improve purification from the last construct by 
minimizing protein degradation through inclusion of protease inhibitors and the addition of 
glycerol to purification buffers to begin with.  
Our work towards the second objective of optimizing conditions for the crystallization of 
BcsC constructs was also successful. The construct screening order for crystal trials in the 
project followed a timeline of BcsCTPR 1-15, BcsCTPR 12-21, BcsCTPR 1-11, BcsCTPR 9-21, and then 
BcsCTPR 4-21. This was based on when our expression/purification trials yielded pure protein to 
work with and led to some crystals undergoing more optimization than others. During crystal 
screening with each of these constructs, numerous crystals were observed, expanded upon, and 
sent for diffraction analysis. BcsCTPR 1-15 and BcsCTPR 12-21, two constructs that together overlap 
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the entire length of the BcsC TPR domain, were successfully crystallized. The labour-intensive 
crystal optimization in this thesis involved tens of thousands of different individual trials, in 
addition to the use of variations in conditions, including wide-ranging protein concentrations and 
ratios to buffer, as well as hundreds of well replications with crystal seeding. Current successes 
with crystallization of two overlapping TPR regions provide a framework to build a model that 
significantly advances the current one for BcsC (90) and other homologous protein models that 
have not presented the benefit of separate sources of structural overlaps. To achieve this goal, the 
screening of C-terminal constructs (BcsCTPR 4-21, BcsCTPR 9-21, and BcsCTPR 12-21) should be 
prioritized along with the crystal optimization of BcsCTPR 12-21 (0.2 M sodium malonate pH 7, 
20% (w/v) PEG 3350), as an N-terminal construct in the final experimental stages. A common 
strategy for conducting these experiments would be to first screen any constructs that have not 
had extensive screening/optimization (BcsCTPR 4-21and BcsCTPR 9-21), followed by a rescreening 
without the His6-tags of BcsC
TPR 12-21, BcsCTPR 4-21, and BcsCTPR 9-21 if no promising hits were 
found in the primary screening (167).  
The final objective of providing a structural model of BcsC had a two-pronged approach. 
The primary method of crystallization has yielded crystals from native BcsCTPR1-15 condition (0.1 
M sodium acetate pH 4.6, 2 M sodium formate), that were diffracted to approximately 3 Å. At 
this resolution, less errors may be inherent compared to the current structural model of BcsCTPR 1-
6, which is 3.27 Å (90). Multiple molecular replacement models were attempted with different 
molecular replacement programs, however, despite the fact that the amino acid homology 
appeared to be high enough to produce a solution (ie. greater than 30% in some cases), these 
efforts were ineffective. As a separate avenue to determine the phases, SeMet derivatives of this 
protein were expressed and purified. This SeMet preparation also led to crystals when subjected 
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to the same conditions as the native crystals, but the SeMet crystals are still growing and, due to 
the time constraints of the thesis, will be pursued as a future direction of this research. However, 
this avenue to structure solution is promising given that there are up to 8 methionine positions 
that can be replaced in BcsCTPR 1-15, leading to an increased probability that there is a 
substructure of these heavy atoms that can be used to solve the structure. Other TPR proteins 
such as BcsCTPR 1-6 (90) and AlgK (74) have also been solved by this method, thereby, offering 
further hope for success in this area. 
Possessing solved crystal structures combined with SAXS data of overlapping constructs 
that would span the entire BcsC TPR domain has begun to answer questions regarding the 
overall orientation within the periplasm and may also provide evidence of conserved residues 
used in protein-protein interactions related to the overall function of the protein. Future evidence 
presented in other solved structures may confirm the theory that numerous TPR folds present 
regions important in ligand binding and protein-protein interactions to generate a fully 
functioning biosynthetic complex. Examples of numerous TPR structures exist that illustrate the 
use of folds as platforms or scaffold for protein interactions that can bind through hydrophobic 
and hydrophilic character and others through stronger forces, such as hydrogen bonding (87, 88). 
In the case of BcsC, it seems logical that some type of strong yet reversible interactions with 
BcsZ occur through binding on the convex surface of the BcsC, which facilitates hydrolysis and 
release of cellulose chains travelling through BcsCs concave surface. However, this is only 
speculation based on current knowledge, and a resolved structure of overlapping BcsC protein 
constructs may elucidate facts regarding the specific structure and function of this process. 
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6. Integrative Nature of This Research 
The discipline of biology encompasses many fields, and this is also true for the sub-discipline of 
protein crystallography. The research conducted throughout this project provided a substantial 
framework for learning about dozens of specialized fields. For example, the initial identification 
of bacterial proteins requires the knowledge to search and navigate seemingly complicated 
computer programs that utilized complex mathematical algorithms to make informed decisions 
on protein stability, construct generation and purification optimization long before the initial wet 
lab research even began. Perhaps even prior to that, was the idea that a specific species of 
bacteria was creating a niche for study through its ubiquitous behaviour in the environment or in 
clinical settings. One such group of bacteria, the Enterobacteriaceae, is home to a large family of 
commensal and pathogenic species that include Escherichia coli, Shigella, Salmonella, and 
countless others that can exist within a community of microbial species, termed a biofilm. 
Billions of dollars have been funneled into the study of biofilms and into bacterial cellulose-
containing biofilms in particular. The pure polymer form of bacterial cellulose has found 
relevance in a new and exciting field of nanocellulose technology that has applications in 
biotechnological, medical, pharmaceutical, and food industries. These developments/applications 
are also rivalled by the interest of researchers in the role cellulose plays in the survival of 
bacterial biofilms through providing increased resistance to anti-microbial agents and protection 
from the immune system. The scope of this research focused on the cultivation of lab strain 
species of bacteria that were used for gene expression in the overproduction of protein for the 
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purpose of downstream applications that were not limited to, but highlighted X-ray 
crystallography and computer algorithms to solve protein structures. Throughout this process the 
disciplines of microbiology, structural biology, the aforementioned biochemistry, analytical 
chemistry, physics, math, computer programs and bioinformatics were all combined to generate 
consistent and reliable results. Overall, the nature of the present research is widely integrative, 
and to specialize in this field, means mastering many aspects from numerous others. 
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Escherichia coli (strain K12) Cellulose Synthase Operon Protein C 
Signal Peptide aa 1-23: MRKFTLNIFTLSLGLAVMPMVEA 
Full Length BcsC Construct aa 24-1157:  
APTAQQQLLEQVRLGEATHREDLVQQSLYRLELIDPNNPDVVAARFRSLLRQGDIDGAQK 
QLDRLSQLAPSSNAYKSSRTTMLLSTPDGRQALQQARLQATTGHAEEAVASYNKLFNGAP 
PEGDIAVEYWSTVAKIPARRGEAINQLKRINADAPGNTGLQNNLALLLFSSDRRDEGFAV 
LEQMAKSNAGREGASKIWYGQIKDMPVSDASVSALKKYLSIFSDGDSVAAAQSQLAEQQK 
QLADPAFRARAQGLAAVDSGMAGKAIPELQQAVRANPKDSEALGALGQAYSQKGDRANAV 
ANLEKALALDPHSSNNDKWNSLLKVNRYWLAIQQGDAALKANNPDRAERLFQQARNVDNT 
DSYAVLGLGDVAMARKDYPAAERYYQQTLRMDSGNTNAVRGLANIYRQQSPEKAEAFIAS 
LSASQRRSIDDIERSLQNDRLAQQAEALENQGKWAQAAALQRQRLALDPGSVWITYRLSQ 
DLWQAGQRSQADTLMRNLAQQKSNDPEQVYAYGLYLSGHDQDRAALAHINSLPRAQWNSN 
IQELVNRLQSDQVLETANRLRESGKEAEAEAMLRQQPPSTRIDLTLADWAQQRRDYTAAR 
AAYQNVLTREPANADAILGLTEVDIAAGDKAAARSQLAKLPATDNASLNTQRRVALAQAQ 
LGDTAAAQRTFNKLIPQAKSQPPSMESAMVLRDGAKFEAQAGDPTQALETYKDAMVASGV 
TTTRPQDNDTFTRLTRNDEKDDWLKRGVRSDAADLYRQQDLNVTLEHDYWGSSGTGGYSD 
LKAHTTMLQVDAPYSDGRMFFRSDFVNMNVGSFSTNADGKWDDNWGTCTLQDCSGNRSQS 
DSGASVAVGWRNDVWSWDIGTTPMGFNVVDVVGGISYSDDIGPLGYTVNAHRRPISSSLL 
AFGGQKDSPSNTGKKWGGVRADGVGLSLSYDKGEANGVWASLSGDQLTGKNVEDNWRVRW 
MTGYYYKVINQNNRRVTIGLNNMIWHYDKDLSGYSLGQGGYYSPQEYLSFAIPVMWRERT 
ENWSWELGASGSWSHSRTKTMPRYPLMNLIPTDWQEEAARQSNDGGSSQGFGYTARALLE 
RRVTSNWFVGTAIDIQQAKDYAPSHFLLYVRYSAAGWQGDMDLPPQPLIPYADW 
